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EXECUTIVE SUMMARY 
For centuries, infectious diseases have been among the top 10 leading causes of death. In 
2015, they accounted for about 11% of 56.4 million deaths worldwide indicating a global 
public health relevance.  
Vaccines provide an opportunity to eliminate or even eradicate infectious diseases. In order 
to maximize the benefit of vaccines while minimizing their risks, it is important to investigate 
infectious disease etiology as well as to continuously monitor and evaluate direct vaccination 
effects as well as indirect vaccination effects through herd immunity. Since vaccines are 
usually administered to healthy people to prevent infectious diseases, the monitoring of the 
safety of vaccines is of high importance. For their evaluation, there is usually no trade-off 
between risk of disease and risk of its treatment as is usually the case for the treatment of 
severe diseases. Vaccine safety is also essential for the acceptance of vaccines in the 
population and thus for high vaccine uptake to enable herd immunity.  
Epidemiological observational studies are a powerful tool to investigate the burden of 
vaccine-preventable diseases, direct and indirect vaccination effects as well as the safety of 
vaccines in a real-world setting, meaning they provide important data as they include—often 
in contrast to randomized controlled trials—older or immunocompromised people as well as 
children or pregnant women, which are most often the target population groups for 
vaccinations. 
Administrative data are a valuable data source for epidemiological observational studies and 
are increasingly used for studies on vaccines and vaccine-preventable diseases. However, a 
comprehensive knowledge of the healthcare system itself, including reimbursement policies, 
but also of the data source and the containing information depth is required.  
This thesis investigates different aspects of vaccines and vaccine-preventable diseases. 
Thus, in a first study, the burden of the vaccine-preventable disease of herpes zoster (HZ) 
and its complications is investigated and in a separate study, the risk of stroke complication 
after HZ infection. Vaccine uptake of the human papillomavirus (HPV) vaccine at the 
population level as well as its indirect impact after vaccine recommendation is assessed. 
Furthermore, this thesis discusses the nested case-control design with respect to its potential 
use for direct effectiveness and safety studies of vaccines. Relevant methodological 
challenges when using different observational study designs based on administrative 
healthcare data as well as methods to control confounding or to reduce bias are elucidated 
and discussed. Finally, this thesis gives outlook on potential challenges of future studies on 
vaccines and vaccine-preventable diseases, especially with regard to newly developed 
therapeutic vaccines for chronic diseases. 
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ZUSAMMENFASSUNG 
Seit Jahrhunderten gehören Infektionskrankheiten zu den 10 häufigsten Todesursachen der 
Menschheit weltweit. Im Jahr 2015 waren rund 11% der ca. 56,4 Millionen Todesfällen auf 
Infektionskrankheiten zurückzuführen, was ein weltweites Public-Health-Problem darstellt.  
Impfstoffe bieten die Möglichkeit der Elimination oder Eradikation von Infektionskrankheiten. 
Um den Nutzen von Impfstoffen zu maximieren und gleichzeitig Risiken zu minimieren, ist es 
wichtig, die Ätiologie von Infektionskrankheiten zu untersuchen, sowie die direkte 
Wirksamkeit als auch die indirekte Wirksamkeit von Impfstoffen durch Bevölkerungseffekte 
(z.B. Herdenimmunität) kontinuierlich zu überwachen und zu bewerten. Da Impfungen 
üblicherweise gesunden Personen—insbesondere Kindern—verabreicht werden, ist zudem 
die Überwachung der Impfstoffsicherheit von großer Bedeutung. Anders als bei der 
Behandlung schwerer Erkrankungen besteht bei der Bewertung der Impfstoffsicherheit 
normalerweise kein Kompromiss zwischen dem Krankheitsrisiko und dem 
Behandlungsrisiko. Die Impfstoffsicherheit ist deshalb auch für die Akzeptanz von 
Impfstoffen in der Bevölkerung und somit für die Durchimpfungsrate wichtig.  
Epidemiologische Beobachtungsstudien auf Grundlage von GKV-Routinedaten sind ein 
wirksames Instrument, um die Krankheitslast von impfpräventablen Erkrankungen, die 
direkte und indirekte Wirksamkeit von Impfungen sowie die Sicherheit von Impfstoffen im 
Rahmen von real-world Daten zu untersuchen. Im Gegensatz zu randomisiert kontrollierten 
Studien können Daten von älteren oder immungeschwächten Menschen, Kindern und 
schwangere Frauen—die oftmals die Zielgruppe für Impfungen darstellen—analysiert 
werden. GKV-Routinedaten stellen dabei eine wertvolle Datenquelle für Studien zu 
Impfstoffen und impfpräventable Erkrankungen dar. Die Durchführung solcher Studien setzt 
ein umfassendes Wissen über das Gesundheitssystem (inkl. der Erstattungsrichtlinien) und 
die Informationstiefe der Daten voraus.  
Die vorliegende Arbeit untersucht verschiedene Aspekte von Impfungen und 
impfpräventablen Erkrankungen. So wird die Krankheitslast von Herpes Zoster (HZ) und 
ihrer Komplikationen und in einer separaten Studie das Risiko von Schlaganfall nach einer 
HZ Infektion untersucht. Es wird die Inanspruchnahme der humanen Papillomavirus (HPV)-
Impfung sowie die indirekte Wirksamkeit der HPV-Impfung nach der Impfempfehlung durch 
die STIKO untersucht. Das Design einer eingebettete Fall-Kontroll-Studie wird hinsichtlich 
der potenziellen Anwendung für direkte Wirksamkeits- und Sicherheitsstudien von Impfungen 
diskutiert. Weiterhin werden relevante methodische Herausforderungen in der Anwendung 
verschiedener Studiendesigns auf Basis von GKV-Routinedaten sowie Methoden zur 
Kontrolle von Confounding und zur Reduktion von Bias aufgezeigt und diskutiert. 
Abschließend gibt diese Arbeit einen Ausblick auf mögliche Herausforderungen zukünftiger 
Impfstudien, insbesondere im Hinblick auf neu entwickelte therapeutische Impfstoffe gegen 
chronische Erkrankungen.  
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PREFACE 
This cumulative doctoral thesis was prepared based on five research articles which are listed 
below and are attached in the appendix.  
By giving the necessary background information (chapter 1), the following sections will place 
the respective articles in the overall context of clinical epidemiology of vaccines and vaccine-
preventable diseases. The results of the individual research articles will be elucidated 
subsequently (chapter 2). Methodological issues on the use of administrative data will be 
discussed, particularly with regard to the strengths and limitations of the different applied 
study designs (e.g., cohort study, nested case-control study, self-controlled case-series 
design and ecologic study) as well as with regard to examples of bias and confounding that 
needed to be addressed within the studies (chapter 3). A final conclusion and an outlook for 
future research on vaccines and vaccine-preventable diseases will be given (chapter 4).   
 
1. Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes 
zoster and its complications in Germany, 2005-2009. Journal of Infection 2014; 
70(2):178-186. [https://doi.org/10.1016/j.jinf.2014.08.018] 
 
2. Schink T, Behr S, Bricout H, Thöne K, Garbe E. Risk of Stroke after Herpes Zoster- 
Evidence from a German Self-Controlled Case-Series Study. PloS One 2016; 11(11): 
e0166554. [https://doi.org/10.1371/journal.pone.0166554]  
 
3. Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. HPV 
vaccine uptake after introduction of the vaccine in Germany: an analysis of 
administrative data. Human Vaccines & Immunotherapeutics 2014; 10(6):1729-33. 
[https://doi.org/10.4161/hv.28450] 
 
4. Thöne K, Horn J, Mikolajczyk R. Evaluation of vaccination herd immunity effects for 
anogenital warts in a low coverage setting with human papillomavirus vaccine – An 
interrupted time series analysis from 2005 to 2010 using health insurance data. BMC 
Infectious Diseases 2017; 17(1):564. [https://doi.org/10.1186/s12879-017-2663-7] 
 
5. Thöne K, Kollhorst B, Schink T. Non-steroidal anti-inflammatory drug use and the risk 
of acute myocardial infarction in the general German population: a nested case-
control study. Drugs- Real World Outcomes 2017; 4:127–137 
[https://doi.org/10.1007/s40801-017-0113-x] 
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Furthermore, a co-authored research article cited in this thesis assesses the 
representativeness of the database on which the five research articles of this thesis are 
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1 BACKGROUND 
1.1 Vaccination - An Opportunity to Eradicate Vaccine-Preventable Diseases 
Infectious disease epidemics have been documented throughout history1. Until the late 18th 
century, infectious diseases constituted the most frequent health risks and causes of death2. 
Due to the improvement of social and hygienic conditions and the isolation of infected 
patients, high infection rates could be reduced3,4. However, reliable infection prevention was 
lacking until the discovery of active immunization by Edward Jenner in 17965. Jenner found 
that by inoculating a human host with cowpox, a protection against smallpox (Latin: vaccinia 
virus) could be induced. Due to this discovery, for the first time in human history, the spread 
of an infectious disease was widely prevented.   
The continuous quality improvement of the smallpox vaccine over time and a consequent 
vaccination campaign conducted by the World Health Organization (WHO) from 1967 to 
19776 led to a sufficiently high vaccination coverage of at least 80% worldwide, rendering 
smallpox the first eradicated human disease in 19797.  
Resulting from this achievement, vaccinations have gained a high social and health policy 
acceptance as they are one of the most successful and economical global health 
interventions to prevent diseases and save lives8.   
WHO initiated the Expanded Program on Immunization (EPI) in May 1974 with the objective 
of developing and expanding global immunization programs and of pursuing the major goal 
of reducing child/infant morbidity and mortality against vaccine-preventable diseases6. Owing 
to the successful development of vaccines and the EPI program vaccines against 26 serious 
vaccine-preventable infections are available to date and many common severe infectious 
diseases, such as diphtheria, tetanus, pertussis, poliomyelitis and measles, are nowadays 
kept under control with the exception of some local outbreaks9. 
However, despite the undeniable success of vaccines against serious vaccine-preventable 
diseases, vaccine opponents are questioning the efficacy, effectiveness and safety of 
vaccines—even though evidence shows that the benefits of preventing morbidity and 
mortality from infectious diseases outweigh the risks10. Furthermore, misguided safety 
concerns in some countries have reduced vaccination coverage, resulting in recurrent 
disease outbreaks of, e.g., pertussis and measles11,12. This indicates that public trust in 
vaccines is an important factor for successful vaccination strategies.  
During the vaccine development process, vaccines are extensively checked for their efficacy, 
immunogenicity and safety in pre-clinical and clinical studies (Phase I–III trials) under ideal 
conditions13. But also after a vaccine has been licensed and/or has been introduced in an 
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immunization program or schedule, it has to be continuously monitored in real-world 
settings14. Observational studies based on administrative data can be used to analyze the 
burden of vaccine-preventable diseases and to evaluate direct and indirect vaccine effects 
after introduction of a vaccine program on the individual and population level as well as to 
monitor the uptake and safety of immunization programs or schedules15. This helps to guide 
vaccination strategies and to ensure that vaccination targets are being reached15. 
Furthermore, the fact that these studies are carried out and published may improve 
vaccination coverage by promoting trust in vaccines’ impact and safety.  
1.2 Clinical Epidemiology of Vaccine-Preventable Diseases 
Clinical epidemiology provides the methodological basis for the investigation of vaccines and 
vaccine-preventable diseases as it composes a conjunction between clinical medicine and 
epidemiology16.   
The following chapter describes the importance of observational studies based on 
administrative data on the burden of disease to expand, e.g., the empirical basis for 
decisions on vaccinations.     
1.2.1 Quantifying Vaccine-Preventable Diseases: Incidence and Prevalence  
The decision-making process regarding the development and introduction of vaccines into an 
immunization program or vaccination schedule is always supported by information on the 
burden of vaccine-preventable diseases and the public health needs in the population8. A 
vaccine will be most accepted and the achievement will be greatest if the vaccine-
preventable disease is a visible and distinguished disease in the community8.  
There are several ways to express the burden of disease by assessing (i) the number of 
cases (e.g., incidence or prevalence), (ii) the number of deaths, (iii) the occurrence of 
(severe) complications after infection, (iv) the number of hospitalizations or (v) disability-
adjusted life years (DALYs)17.   
The incidence and prevalence estimation of a disease is among the basic measures of 
disease burden calculations in epidemiology18.  
While the incidence rate of an infectious disease measures new events of that disease per 
unit of time, the prevalence is the proportion of persons with the disease at a specific time 
point. Both measurements are related to each other by the duration of the disease19.  
Prevalence of a disease is not only determined by the causes/risk factors of the disease, but 
also by the determinants of disease survival and is therefore less suitable for studies of 
etiologic research20.  
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Incidence estimation makes is easier to describe and investigate cause and effect as it is 
certain that the exposure has preceded the outcome.  
Therefore, for burden of disease, vaccine effectiveness and safety cohort studies, incidence 
measures are more useful (i) to study causes of diseases as their investigation is based on 
(comparing) incidence rates among subgroups with different risk factors or different risk 
exposures18 or (ii) to investigate changing patterns of a disease within a population over time. 
Furthermore, as vaccination usually occurs before the disease occurs, the main interest of 
vaccine studies is to investigate potential changes (reduction) of the incidence rate of the 
targeted disease after vaccination (chapter 1.3.2 and 1.3.3). In the context of vaccine 
effectiveness and safety studies, it is possible to investigate a presumable causal 
relationship of the occurrence of new adverse events after vaccination (chapter 1.3.4). 
An example for a burden of disease study included in this thesis is the cohort study on 
incidence rates of herpes zoster (HZ) and its complications21. This study presents age-, sex- 
and immune status-specific incidence estimates on HZ and its complications as well as 
proportions of postherpetic neuralgia (PHN). Results of this study may help to define 
population subgroups with the highest disease burden and the greatest need of being 
targeted by vaccination strategies.    
1.2.2 Risks of Complications after Infectious Diseases 
Short- and long-term consequences (i.e., complications and sequelae) of an infection reflect 
the risk of severe diseases and/or premature mortality as well as conditions that limit the 
quality of life like PHN. Hence, besides protection against the infectious agent itself, 
vaccination particularly confers protection against severe complications and diseases. 
Especially immunocompromised and older patients are at increased risk of complications 
after an infection.  
For a long time, vaccine-preventable diseases and chronic diseases were considered 
independent entities. But in recent years, it has been recognized that many infectious agents 
can lead to severe complications and chronic diseases like cardiovascular diseases (CVDs), 
chronic respiratory and endocrine diseases as well as cancer22. Since these diseases are 
globally of major public health relevance, their prevention is highly important and the 
opportunity to vaccinate against severe chronic diseases or cancer would have a major 
public health impact.   
However, it is often still difficult to demonstrate the causal relation between a virus infection 
and the development of particular cancer types due to long latency. This is due to the fact 
that multiple risk factors like environmental, biologic and lifestyle factors may contribute 
jointly or independently to carcinogenesis23. However, the causal association of an infection 
with the human papillomavirus (HPV) and the development of cervical cancer has been 
1 BACKGROUND 
 
4 
 
ascertained by several molecular studies as well as epidemiological studies24,25. Currently, 
the finding that HPV infection (i.e., most frequently high-risk types 16 and 18) is a necessary 
cause of cervical cancer development is considered scientific evidence24,26. Furthermore, 
non-cancer causing types of HPV (especially low-risk types 6 and 11) are associated with the 
development of anogenital warts (AGWs)27. Considering the long latency between HPV 
infection and cervical cancer development it would require an extremely long follow-up and 
enormous study size for observational studies to estimate the HPV-vaccination impact 
regarding the burden of the HPV-related infectious disease outcome cervical cancer. Instead, 
surveillance of outcomes with less lead time—as is the case with AGWs—provides early 
outcome measures for vaccine effectiveness (chapter 1.3.2) and impact studies (chapter 
1.3.3) on the population level28. Furthermore, mathematical predictive models provide a 
valuable tool to examine long-term effects of vaccination strategies that cannot be 
investigated during the study period of observational studies29.  
An example for a putative cardiovascular complication after a varicella zoster virus (VZV) 
infection is stroke, which occurs as VZV invades cerebral arteries and induces VZV 
vasculopathy30. Even though causality between HZ and stroke has been suggested31, the 
adequate adjustment for potential confounding factors, such as myocardial infarction, 
transient cerebral ischemic attack and antithrombotic medications, etc. is challenging in 
observational studies32. In the SCCS-study33 included in this thesis, we used the SCCS 
design to investigate an increased risk of stroke within 3–4 weeks after an HZ infection, 
adjusted for both, time-variant as well as time-invariant confounding factors33. 
The examples of complications (e.g., AGWs as an earlier outcome for cervical cancer, stroke 
after HZ infection) caused by infectious agents (e.g., HPV, VZV) show the large potential and 
novel opportunities for primary prevention interventions aiming to reduce the burden of 
infectious diseases.  
1.3 Vaccination as the Primary Prevention of Vaccine-Preventable Diseases  
Effective immunization programs/schedules need to vaccinate a sufficiently high proportion 
of susceptible persons to gain herd immunity34. Furthermore, such vaccination strategies 
need to boost vaccination rates before immunity drops below a protective level to prevent 
potential outbreaks35.  
There are two types of vaccines to combat vaccine-preventable diseases: Live attenuated 
vaccines and inactivated vaccines36,37 (Table 1). 
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Table 1: Overview of different types of vaccines with examples and respective contents. 
Types of vaccines 
Examples of vaccines against 
specific vaccine-preventable 
diseases 
Vaccine contents 
Live attenuated vaccines 
E.g., measles, mumps, rubella, 
varicella, rotavirus, herpes zoster 
(Oka/Merck), influenza (nasal spray), 
polio (oral) or yellow fever vaccine 
Derived from weakened or altered 
disease-causing pathogens, that 
have been processed under 
laboratory conditions 
Inactivated vaccines E.g., polio vaccine (injection) 
Made from microorganisms which 
have been killed by heat or chemical 
processes 
 E.g., diphtheria and tetanus Contain inactivated toxins 
E.g., influenza (injection), human 
papillomavirus, herpes zoster (HZ/su; 
GlaxoSmithKline (GSK), pertussis or 
pneumococcal vaccine for children 
Contain only segments of the 
pathogens 
 
While live attenuated vaccines are often able to induce a strong and long-lasting immune 
response, a reversion to virulent wild-type strains may occasionally occur—especially in 
immunocompromised patients—causing the disease38. One example for a very rare but 
possible reversion to the more virulent profile of wild virus is the oral polio vaccine (OPV)39. 
However, while inactivated vaccines cannot exhibit reversion to virulence they tend to 
produce a weaker immune response and therefore require multiple booster injections. 
Furthermore, they contain immunologic adjuvants to enhance vaccine efficacy, but they are 
also suitable for immunocompromised people40.  
In the case of a new inactivated herpes zoster vaccine (HZ/su; GSK vaccines), efficacy of 
97.2% against HZ41 vs. 51.3% of the live attenuated zoster vaccine Zostavax42 throughout all 
age groups has been reported and is suggested to be due to the new adjuvant system 
(AS01B) of the inactivated vaccine41. Adjuvants, in turn, are often suspected of causing 
adverse vaccine reactions43–45 (e.g., the autoimmune/inflammatory syndrome induced by 
adjuvants (ASIA))46. While all licensed adjuvant vaccines have shown a favorable benefit-risk 
ratio47, the choice whether a vaccine should be recommended within a particular target 
population is crucial. 
The following chapter will shortly introduce the work of the German Standing Committee on 
Vaccination [Ger.: Ständige Impfkommission (STIKO)] regarding the decision-making 
process to recommend vaccines for immunization schedules in specific target groups. 
Furthermore, by evaluating vaccines and their impact on the population level, the next 
chapter will also provide information on direct and indirect vaccination measures as well as 
examples for debates on adverse vaccination reactions which might impede vaccine uptake. 
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1.3.1 Vaccine Recommendation by the German Standing Committee on Vaccination 
[Ger.: Ständige Impfkommission (STIKO)] 
The World Health Organization (WHO) recommends several routine vaccination schedules 
globally. However, depending on the burden of disease in the population, the availability of 
an efficacious, effective and safe vaccine, economic factors and the level of priority that is 
placed on the vaccine-preventable disease, the immunization focus varies from country to 
country. Therefore, national vaccination schedules are developed, too. 
In Germany, the national vaccination schedule is developed by an independent committee of 
experts called STIKO, which was established in 197248. STIKO investigates the individual 
risk-benefit ratio, the population-based epidemiology as well as effects of a nationwide 
vaccination schedule and defines criteria for the assessment of adverse vaccination events. 
Together with the Protection against Infection Act [Ger.: Infektionsschutzgesetz (IfSG)], 
STIKO was incorporated into German law in 2001. Vaccination is not compulsory in 
Germany. However, STIKO recommendations are considered the medical standard. 
Furthermore, since 2007, vaccines recommended by STIKO according to section (§) 20 (3) 
of IfSG have been the basis for the immunization guidelines of the Joint Federal Committee 
(G-BA) and reimbursement is—by inclusion in the guidelines—compulsory for statutory 
health insurance providers (SHIs) in Germany.  
Before the recommendation of a new or updated vaccine, STIKO reviews all available data 
about the vaccine from clinical trials and other available (observational) studies. The STIKO 
experts conduct a risk-benefit evaluation by investigating the individual benefit of vaccinated 
persons. Furthermore, population-level benefits due to herd immunity but also negative 
effects of vaccination programs/schedules (e.g., pathogen strain replacement phenomena, 
age shift of the disease burden) or cost-effectiveness analyses are evaluated.  
For key questions regarding vaccine efficacy, effectiveness and safety, systematic reviews 
are conducted according to PICO questions (patient, intervention, comparator, outcome) and 
are ranked according to the GRADE methodology (grading of recommendations assessment, 
development and evaluation)48.  
For key questions related to e.g. burden of disease or vaccine acceptance systematic and/or 
exploratory literature searches are conducted, too.  
Based on the results and quality of the available evidence obtained from data and 
information identified from the literature, STIKO debates all relevant key questions and 
criteria and finally decides whether a recommendation is given. New or updated 
recommendations are usually published once a year (usually in August) in the national 
epidemiological bulletin.  
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1.3.2 Direct Vaccination Effects: Vaccine Efficacy and Effectiveness 
The public health importance of a vaccine is, on the one hand, related to the direct protective 
effect for the person receiving the vaccine and, on the other hand, to the indirect effects for 
others in the population (chapter 1.3.3). Population-based observational studies provide a 
valuable approach to measure vaccine effectiveness49–51.  
Vaccine Efficacy 
Vaccine efficacy is defined as the percentage reduction of the vaccine-related disease 
among patients vaccinated according to the immunization schedule compared to 
unvaccinated patients (placebo group)52. This is usually conducted in a randomized 
controlled trial (RCT) “per protocol” with strict inclusion and exclusion criteria (i.e., excluding 
persons who are not included in the recommended schedule) as well as close monitoring to 
investigate the biologic performance capacity of the vaccine in a controlled environment 
under optimal conditions with usually healthy participants and 100% vaccine uptake53. Due to 
randomization and allocation concealment, RCTs have high internal validity, and bias that 
could lead to invalid study results is minimized. This, however, often hampers 
generalizability54. As this thesis does not include vaccine efficacy studies, these will not be 
described in more detail. They have only been mentioned to point out the differences to 
vaccine effectiveness studies described in the following. 
Vaccine Effectiveness 
Due to the fact that the application of a placebo vaccine could place the persons in the 
placebo group at risk of serious complications55, it would be unethical to perform placebo-
controlled RCTs after a vaccine has been introduced into a population. Vaccine effectiveness 
is therefore usually assessed in observational studies (e.g., cohort studies, case-control 
studies, nested case-control studies)49,52. It measures—similarly to vaccine efficacy—the 
percentage reduction in the incidence rate among vaccinated and unvaccinated persons but 
under real-world conditions; namely, in much larger populations over longer periods of time, 
within different healthcare systems, with concomitant drug use and vaccination application, 
including pregnant women, healthy children (i.e., no premature children), older persons or 
persons with underlying medical conditions which is usually not the case in RCTs. However, 
occasionally some RCTs also include some of these vulnerable population groups, e.g., 
RCTs on vaccine effectiveness and safety during pregnancy for mother and fetus.   
One can compare vaccine effectiveness of a full vaccine series versus an incomplete 
vaccine series or no vaccination and measure effectiveness of a pathogen-specific outcome 
(e.g., incidence of clinically defined infections, laboratory-confirmed infection or vaccine-
serotype diseases)49.  
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Administrative data can be very helpful as prompt evaluation of vaccine effectiveness of, 
e.g., HZ vaccine effectiveness56 or pneumococcal polysaccharide vaccine effectiveness57 is 
important and these data have the advantage of being timeless and efficient58. However, to 
evaluate vaccine effectiveness can be also very challenging as is the case with influenza 
vaccine effectiveness due to the antigenic drift and shift of the virus genome. Consequently, 
vaccine effectiveness can vary from season to season and needs to be monitored 
accordingly.  
The nested case-control study design and the case-control study design can and already 
have been used to evaluate the effectiveness and safety of licensed vaccines after 
introduction in public health programs or vaccination programs/schedules50,51,59–61. Since this 
thesis includes a nested case-control study (using risk-set sampling) that investigated drug 
safety issues62, this study design will be discussed with a transferred focus on the 
methodological challenges (i.e., misclassification and selection bias) within the scope of 
influenza vaccine effectiveness63,64 based on administrative data (chapter 3.1.2 and 3.2.1). 
Furthermore, alternative study design options will be discussed that are more suitable to 
investigate influenza vaccine effectiveness but potentially need additional data by linkage 
with other data sources (chapter 3.1.3). 
Since vaccine effectiveness studies can evaluate the vaccination strategies on the individual 
level, the respective results help to optimize vaccine uptake and guide political decision 
processes by, e.g., identifying preferred vaccine product classes or by stimulating the 
improvement of vaccines65. However, vaccine effectiveness studies cannot evaluate the 
impact of a vaccination program/schedule within the population.  
1.3.3 Indirect Vaccination Effects: Herd Immunity Effects Resulting from Vaccine 
Uptake and Coverage - Measured by Vaccine Impact Studies 
After a vaccination program/schedule has been implemented on the population level, it is 
important to monitor the impact of the vaccine on the target disease. This way, the 
effectiveness and the potential benefit of the vaccine can be quantified.  
Vaccine Uptake and Coverage 
Vaccination coverage is used as an indicator for the success of vaccination strategies and is 
helpful for vaccine effectiveness and adverse vaccination signal interpretation66–68. Coverage 
estimates are usually measured by routine administrative data, sources from immunization 
information systems, vaccination cards or coverage surveys. The estimation of the 
percentage vaccination coverage relying on administrative data is based on the number of 
vaccinated persons during a specific period (numerator information) divided by the total 
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number of persons eligible for vaccination (denominator information)67. Figure 1 shows the 
immunization coverage for some important vaccine-preventable diseases in Germany.  
 
 
Figure 1: German immunization coverage for measles, human papillomavirus (HPV), influenza, 
and rotavirus vaccine (reference source: epidemiological bulletin 01/2017)69. 
 
In Germany, data from surveys or vaccination cards are the sole primary data source for 
vaccine coverage estimation68. However, one study compared external validated vaccine 
coverage estimation from administrative health insurance data with survey data and found 
good agreement between the data sources, meaning that analysis of administrative health 
insurance data can be a useful data source for the monitoring of vaccination coverage or 
vaccine uptake studies already shortly after a new vaccine has been introduced or for the 
investigation of the general acceptance of already recommended vaccines70.  
In one study71 included in this thesis, an estimation of the vaccination coverage rather than 
the vaccine uptake was not possible, since knowledge about the vaccination status before 
the study period was not available. Consequently, vaccine uptake has been calculated by 
dividing the number of females who received at least one dose of HPV vaccine by the 
number of insurees in the respective age group, demonstrating 32.2% uptake in the 
recommended age groups (12–26 years) with a peak uptake in females aged 14–16 years71, 
which is low compared to other countries72–74. 
Monitoring vaccine coverage is highly important in order to identify areas and groups with low 
vaccination coverage or high drop-out rates between the first and final dose75. Furthermore, it 
helps to understand reasons for low coverage, so that public health departments, healthcare 
partners and schools can help to improve vaccination coverage by increasing acceptance 
and vaccine uptake. Moreover, the potential for outbreaks of vaccine-preventable diseases 
can be identified.  
Monitoring vaccine coverage is not only relevant for the targeted diseases. Introduction of 
one vaccine can also affect the coverage of other vaccines76. On one hand, there may be 
1 BACKGROUND 
 
10 
 
catch-up vaccinations which could increase coverage of all routine vaccines. On the other 
hand, rumors about the safety of a new vaccine could lead to a reduced overall immunization 
coverage as parents may refuse vaccination of their children68.  
Vaccine Impact 
Vaccine impact is defined as the reduction in incidence of the disease in a population 
targeted by a vaccination strategy15. For the estimation of vaccine impact, it is necessary to 
compare populations with and without an introduced vaccination program/schedule or to 
compare disease incidence attributable to a new vaccination program/schedule within the 
same population in the years before and after the intervention (“before/after studies”) usually 
conducted in ecologic studies using interrupted time-series analysis50,77–80.  
One study included in this thesis assessed the HPV vaccine impact by investigating the 
incidence of anogenital warts (AGWs) before and after HPV vaccine introduction81 
suggesting herd immunity effects among males of similar age groups as that of the vaccine-
recommended age groups of females. 
Herd Immunity 
Herd immunity implies that a rather high level of immunity in a community (vaccine coverage) 
can serve to protect susceptible (unimmunized) persons34,82. Such a collective immunologic 
protection represents an indirect effect of a vaccine exceeding the individual protection and 
impacting the population as a whole. The level of population immunity which is needed to 
interrupt transmission is defined as the herd immunity threshold (HIT) which is given by 1-
(1/R0)83. R0 as the basic reproduction number is the number of secondary cases which one 
case would generate on average over the course of its infectious period in a completely 
susceptible population84. In general, the larger the value of R0, the harder it is to control an 
epidemic. The basic reproduction number is also affected by the duration of the infectious 
period, the infectiousness of the organism and the number of susceptible people in the 
population85. A vaccination program/schedule does not need to achieve 100% coverage to 
provide herd immunity against diseases in a community, e.g., to eliminate Haemophilus 
influenzae type b (Hib), a vaccine coverage of less than 70%86,87 is sufficient. However, in the 
case of measles, a vaccine coverage of approx. 95% is necessary for the elimination of the 
disease88 (Figure 1). If the incidence reduction in vaccinated and unvaccinated persons is 
higher than the coverage level, there is a strong indication for herd immunity effects. This 
also applies to incidence reduction in age groups or sexes besides the target vaccination 
group as has been seen in the HPV-study81.  
For sexually transmitted infections (STIs), a high level of vaccine-induced immunity in one 
sex can induce herd immunity in the other sex, but this also depends on a complex 
combination of other factors (e.g., vaccination coverage and sexual behavior)89–91. Due to 
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assortative mixing patterns, STIs will be more concentrated among high-risk persons as 
these have the greatest potential to infect others89. Therefore, in certain populations, high-
risk persons of both sexes require immunization by vaccination to gain herd immunity 
effects89,91. 
A decrease of disease incidence in all age groups may result in an increase of the mean and 
median age of first infection, which in turn can cause more serious complications if infection 
takes place later in life (e.g., rubella infection during pregnancy)92. Thus, it is necessary for 
vaccination programs/schedules to maintain a high coverage in subsequent birth cohorts as 
numbers of susceptible persons will accumulate in older age groups.    
Only contagious diseases transmissible among humans can be eradicated by herd immunity 
due to reduced transmission from one person to another93. Therefore, herd immunity cannot 
be achieved if infectious agents can also use hosts other than human individuals (e.g., 
tetanus (Clostridium Tetani) or tick-borne encephalitis (TBE) [Ger.: Frühsommer-
Meningoenzephalitis (FSME-virus)]).   
1.3.4 Vaccine Safety Studies of Adverse Vaccination Reactions after Marketing 
Approval 
Potential safety concerns regarding vaccines can have a large effect on vaccine uptake and 
coverage. Once its efficacy and safety have been demonstrated in a multi-stage test 
procedure (Phase I–III), is a new vaccine licensed by the European Medicines Agency (EMA) 
Committee for Medical Products for Human Use (CHMP) for the European Union (EU) and 
respectively by the German Federal Agency for Sera and Vaccines—the Paul-Ehrlich-
Institute (PEI)—for Germany. 
As no vaccine is perfectly safe or effective, potential risks accompany its benefits. Vaccines 
are given to healthy persons, which is why tolerance of adverse reactions is even lower than 
for pharmaceuticals which are mostly given to ill persons for curative purposes. Serious so-
called adverse vaccine reactions (AVRs) after vaccination are very rare94. However, vaccine 
safety concerns attract great attention95,96. For AVRs, special reporting obligations apply: 
According to § 6 (1) of the IfSG, already the suspicion of an AVR which exceeds the usual 
level of an inoculation reaction is subject to reporting. Furthermore, confirmed and suspicious 
AVRs are reported to the PEI directly or via the local Health Office. The PEI maintains a 
database that includes both suspicious messages and confirmed cases of adverse reactions 
associated with vaccinations. Potential risks are published and, if necessary, further 
investigated in clinical and epidemiological studies. Although AVRs from spontaneous 
reporting provide warning signals of risks and can function as a useful tool to provide 
hypotheses of unknown AVRs, it is not possible to determine the risks and frequency of 
specific AVRs due to underreporting and missing information on the vaccinated individuals 
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necessary for denominator assessment97. Therefore, vaccine safety issues need to be 
investigated by epidemiological observational studies in a real-world setting as knowledge on 
the benefit-risk profile during the approval process is limited98. These studies play an 
important role for a sound evidence base regarding population-based vaccine effects of rare 
and severe AVRs once a vaccine has been introduced to the population99.  
Awareness of background incidences of possible vaccine-related adverse events can provide 
valuable information to investigate whether a disease/adverse event occurs after vaccination 
at disproportionally high rates100 as AVRs do not exhibit specific characteristics but manifest 
themselves like any other newly occurring disease. Most serious AVRs are rare and it is 
challenging to investigate and differentiate causality and temporal association by chance101. 
As already mentioned, spontaneous reporting systems can only “signal” emerging AVRs. If 
epidemiological data indicate causality of severe AVRs, the vaccine will be removed from the 
market (e.g., in Germany: FSME vaccine TicoVac in 2001102, Hexavac® in 2005103).  
Unfortunately, misleading reports on AVRs may result in a decline or disruption of 
attendance to vaccination programs/schedules101. One example is the false association of 
the MMR vaccine with the risk of autism which resulted in decreasing uptake of measles 
vaccine104–106.  
Another example is the erroneously suggested relationship of a teenage death shortly after 
HPV vaccination in Austria. However, due to the available background rates of sudden 
deaths in adolescents in Austria, the HPV vaccination program could be continued101. During 
2015, there were case reports of the Complex Regional Pain Syndrome (CRPS) and 
Postural Orthostatic Tachycardia Syndrome (POTS) occurring in young women after HPV 
vaccination107,108. However, in November 2015, the European Medicines Agency’s 
Pharmacovigilance Risk Assessment Committee (PRAC) investigated pre- and post-
licensure data as well as background incidences of the diseases and concluded no evidence 
to support causality109–111.  
Guillain-Barré syndrome is another good example of an AVR as several large-scale 
vaccination programs/schedules were associated with an increased number of cases of 
Guillain-Barré syndrome112. The assessment of such cases before and after vaccination has 
therefore been of high priority113.  
The inappropriate assessment of vaccine safety data or the non-scientific social-media 
attention (e.g., on Facebook, etc.) on single individual cases suffering from AVRs could 
severely distort and undermine the impact of mass vaccination campaigns. In the case of 
HPV vaccination, an enormous public health debate has been dominated by safety concerns 
resulting in decreasing vaccination coverage and thus ignoring the fact that an effective 
vaccine is available against cervical cancer.   
1 BACKGROUND 
 
13 
 
Post-marketing observational studies on vaccines based on administrative data can 
contribute to the monitoring of direct and indirect vaccine effects, as well as of AVRs and 
boost trust in vaccines’ impact and safety. 
1.4 Data Sources for Clinical Epidemiology of Vaccine Effectiveness and Safety and 
on Vaccine-Preventable Diseases  
1.4.1 Primary and Secondary Data 
Primary as well as secondary data can be used as data sources for epidemiological studies 
on vaccines and vaccine-preventable diseases70.  
In Germany, primary data on vaccination uptake and coverage and on the immune status 
have been specifically collected in health surveys for the purpose of the respective study and 
research question. Solely or combined with secondary data, they provide a valuable 
contribution to monitoring the coverage or uptake of vaccines and to the evaluation of 
compliance with vaccination schedules in Germany. A comparison and overview of 
characteristics and vaccine status assessment of primary and secondary data for studies on 
vaccines and vaccine-preventable diseases is given in Table 2. 
In Germany, there are various primary data sources for studies on vaccines, i.e., primary 
data from surveys such as kindergarten entrance examinations (KEEs) that are performed 
merely in a few federal states, population surveys (e.g., the population-based German Health 
Interview and Examination Survey for Children and Adolescents (KiGGS) or the German 
Health Interview and Examination Survey for Adults (DEGS)) or school entrance 
examinations (SEEs)70.  
Secondary databases can be divided into medical record databases and administrative 
claims databases114. While data from medical record databases are derived from electronic 
patient files, administrative claims databases contain data obtained by health insurance 
providers or state-financed healthcare systems mostly in the field of healthcare services and 
quality control98,115 or other administrative purposes116. Therefore, it may not contain all 
information of interest115. The information available in both databases is mostly similar, even 
though medical record databases often additionally contain information on lifestyle factors 
(smoking, body mass index (BMI) or alcohol consumption) which is missing in administrative 
claims data.  
Commonly in administrative claims data, information on drug prescriptions as well as 
outpatient and inpatient data are reported to the patient’s health insurance provider for 
reimbursement purposes. Additionally, the available information on sociodemographic 
information can be used for the investigation of the respective research questions. As an 
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advantage, persons who are rarely investigated in RCTs (older or immunocompromised 
persons, severely diseased or deceased persons, infants or pregnant women) or are difficult 
or impossible to reach through field studies are included in these data98. For these population 
groups, vaccine effectiveness, impact and safety studies conducted under real-world 
conditions based on secondary data can provide important information. In addition, since 
secondary data are already available, analysis can usually be performed promptly and cost 
effectively98. The validity of data related to applied vaccinations is high since the 
reimbursement of the applied vaccine is directly related to the deduction of the vaccination 
[Ger.: Impfziffer]117. However, some limitations need to be mentioned for studies on vaccines 
with German claims data. This topic will be discussed in more detail within the context of the 
German Pharmacoepidemiological Research Database (GePaRD) in the next chapter. 
GePaRD—as an administrative claims database—represents the basis of the individual 
research articles included in this thesis.   
 
Table 2: Comparison of primary and secondary data sources for studies on vaccine 
effectiveness and safety and on vaccine-preventable diseases in Germany. 
 
Characteristics Primary data Secondary data 
Data sources - KEE, SEE, KiGGS, DEGS - Obtained from data sources 
with a different original 
purpose, e.g., by health 
insurance providers collected 
for reimbursement purposes 
(claims databases) 
- Electronic medical records from 
general practitioners or 
hospitals (medical record 
databases) 
Vaccination status 
assessment 
- Measured, documented or 
remembered ad hoc by the 
respective individual 
- Information on vaccination 
status and coverage, e.g., from 
reimbursement of vaccination 
(necessary detail may not be 
available, e.g., differentiation of 
different vaccine types) 
Information on lifestyle-
related factors (e.g., 
smoking, alcohol intake, 
etc.) 
- Measured, documented or 
remembered ad hoc by the 
respective individual 
 
- Partly available in medical 
record databases, not in claims 
databases 
Vaccination program and 
campaign assessment 
- Ad hoc knowledge and attitudes 
towards vaccination and 
programs/schedules (KiGGS, 
DEGS) 
 
- Compliance with vaccination 
schedules and immunization 
programs 
Time and cost efficiency - Ad hoc data collection requires 
time and personal/monetary 
resources 
 
- Data are mostly promptly 
available and inexpensive 
Individual immune status - Supplied by vaccination cards 
and serological tests (KiGGS, 
- Partly available in medical 
record databases, not in claims 
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Characteristics Primary data Secondary data 
DEGS) 
 
databases 
Regional coverage 
comparisons  
- Vaccination coverage 
assessment is possible for all 
recommended childhood 
vaccinations for a specific cohort 
of children (SEEs) 
- Population-based data of 
selected vaccinations by age or 
sociodemographic status 
available (KIGGS, DEGS) 
 
- Population-based coverage 
data of recommended and 
reimbursed vaccinations can be 
assessed by age (data 
available since the time data 
collection started, e.g., 
associations of statutory health 
insurance physicians (ASHIP) 
data since 2004) 
Trend analyses - Possible for complete cohorts by 
all recommended childhood 
vaccinations 
- Follow-up of birth cohorts and 
vaccination incidence 
- Cumulative vaccination 
incidence by a defined age and 
year  
- Trends over time 
Disease incidence 
estimation 
- Not possible in surveys - Estimation of disease incidence 
possible 
Vaccine safety assessment - Generally not possible 
(sometimes surveys ask for 
AVRs) 
- Estimation of rather acute, late 
and rare events possible 
Bias - Recall bias possible  
- Interview bias possible 
- Selection bias (due to non-
responders) possible 
- Recall bias not possible 
- Interview bias not possible  
- Selection bias (due to non-
responder) not possible 
Abbreviations: Associations of Statutory Health Insurance Physicians (ASHIPS), kindergarten entrance 
examination (KEE), school entrance examination (SEE), German Health Interview and Examination Survey for 
Children and Adolescents (KiGGS), German Health Interview and Examination Survey for Adults (DEGS). 
1.4.2 The German Pharmacoepidemiological Research Database (GePaRD) 
The German Pharmacoepidemiological Research Database (GePaRD), which was 
established by and is maintained at the Leibniz Institute for Prevention Research and 
Epidemiology – BIPS, currently consists of data from four statutory health insurance 
providers (SHIs) with a total of more than 20 million insured persons over all data collection 
years118. Two SHIs are operating nationwide and the other two, smaller ones in Bremen and 
in the Northwest German region. GePaRD represents nearly 17% of the German population 
throughout all federal states in Germany118. In addition to sociodemographic core data, 
GePaRD includes outpatient care data and inpatient diagnoses and procedures as well as 
prescription data of all individuals enrolled in one of the four SHIs since 2004. The 
description of the structure of GePaRD and contained information due to the linkage with the 
central pharmaceutical reference (CPR) database is displayed in Figure 2. Diagnoses are 
coded according to the International statistical classification of diseases and related health 
problems, 10th revision, German modification (ICD-10-GM). Inpatient data comprise 
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diagnostic and therapeutic procedures as well as outpatient surgeries that are represented 
via the Operation and Procedure Key (OPS). Further information contained in inpatient data 
is the date of admission and discharge (incl. the reason for hospital discharge/death) as well 
as different types of diagnosis (admission, main discharge, secondary and ancillary 
diagnosis).  
Outpatient data comprise types and dates of diagnostic and therapeutic procedures and 
diagnoses on a quarterly basis including the diagnostic certainty (certain, suspected, 
excluded, and status post diagnosis). Outpatient therapeutic services are coded according to 
the physician’s fee schedule [Ger.: Einheitlicher Bewertungsmaßstab (EBM)] that defines the 
content of and the payment for each outpatient service. Outpatient prescription data include 
information on prescriptions dispensed in a pharmacy and reimbursed by the respective SHI. 
Further information included in prescription data are the dates of the prescription and 
dispensation, the number of prescribed packages, the specialty of the prescribing physician, 
and the central pharmaceutical number [Ger.: Pharmazentralnummer (PZN)]. Via linkage 
with an internal reference database at BIPS further information such as the defined daily 
dose (DDD), information on generic and brand name, packaging size, strength and the 
Anatomical-Therapeutic-Chemical (ATC) code, can be added. But information on prescribed 
daily doses or the planned duration of therapy is not included.  
GePaRD data can only be used after the respective research project has been officially 
approved by the contributing SHIs and their governing authorities98,118.  
For studies on vaccines, some particularities apply: standard vaccinations are not prescribed 
to individual patients but included in the so called “Sprechstundenbedarf” (medical products 
for use at a physician’s office only) which cannot be identified in the database. Via outpatient 
EBM codes that are used for reimbursement of, e.g., administration of recommended 
vaccines, the application of vaccines can be identified. However, before 2008, there was no 
uniform EBM coding and EBM codes for administered vaccines varied in 2007/2008 between 
the regional Associations of Statutory Health Insurance Physicians (ASHIPs). There were 
also differences among the SHIs in the doses and over time as every regional ASHIP could 
negotiate individual vaccine agreements [Ger.: Impfvereinbarungen] with the different SHIs. 
Additionally, EBM codes related to vaccinations are updated (and consequently changed) 
frequently. Since July 2008, uniform EBM codes for all ASHIPs have been introduced for the 
identification of the different administered vaccines and for the identification of completed or 
incomplete vaccine schedules119. However, in reality, the new uniform EBM codes were not 
introduced in all ASHIP regions directly. Furthermore, the EBM codes do not differentiate 
between different kinds of vaccines if these are administered in the same way. For example, 
the bivalent (Cervarix®) and the quadrivalent (Gardasil®) HPV vaccination have the same 
EBM code in Germany. The same is true, e.g., for certain pneumococcal vaccines and 
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subcutaneous influenza vaccines. Resultingly, the distinction between those vaccines based 
on administrative claims data is impeded. In addition, in the case of the HPV vaccine, during 
the introduction period of specific EBM codes, only a few federal states had specific EBM 
codes for HPV vaccinations in females older than the recommended age groups (> 17 years) 
as only some SHIs reimbursed the vaccine for these older females. Consequently, not all 
vaccinations in older females can be identified across Germany for these years.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Structure and content of GePaRD and of the CPR. 
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1.5 Objectives 
The individual research articles included in this thesis are all based on administrative claims 
data from health insurance providers contained in the GePaRD database. These studies 
aimed (i) to investigate the burden of vaccine-preventable diseases and complications to 
extend the data basis for a vaccine recommendation decision process, (ii) to evaluate 
vaccine uptake and the impact of an already introduced and recommended vaccine in the 
general population and (iii) to apply a nested case-control study design to its potential use for 
vaccine effectiveness and safety studies.  
The following objectives were addressed in this thesis: 
1. to estimate data on the disease burden of herpes zoster, its complications and 
postherpetic neuralgia throughout all age groups and stratified by immune status,  
2. to assess the risk of stroke as a major complication after the onset of herpes zoster, to 
investigate the risk of stroke subtypes, the role of herpes zoster location and the time interval 
between herpes zoster onset and stroke, 
3. to describe the HPV vaccine uptake in Germany after reimbursement of the vaccine on a 
broad regional level, 
4. to assess potential vaccination herd immunity effects in a low HPV coverage setting in 
Germany after the HPV vaccine recommendation and  
5. to apply the method of a nested case-control study design with risk-set sampling in a 
defined cohort to estimate population-based risks of acute myocardial infarction (AMI) for 
individual and widely used nonsteroidal anti-inflammatory drugs (NSAIDs). Although this 
study design was not applied to a vaccine-related topic, it is a valuable method for vaccine-
related studies as discussed later. 
Based on the conducted research articles, various methodological aspects will be described 
and discussed in the context of clinical epidemiology of vaccines and vaccine-preventable 
diseases on the basis of administrative claims data. 
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2 EXECUTIVE SUMMARY OF RESULTS OF INDIVIDUAL 
RESEARCH ARTICLES  
This chapter summarizes the most important results of the individual research articles 
preceded by a brief introduction of the respective viral disease. 
2.1 Burden of Infectious Diseases and Potential Risk of Cardiovascular Diseases 
after an Infection (Using the Example of Herpes Zoster) 
Herpes zoster (HZ) is a viral disease caused by an endogenous reactivation of the varicella 
zoster virus (VZV)120. Primary infection usually occurs in childhood and causes varicella 
(chickenpox). Afterwards, the virus remains latent within sensory dorsal roots of the cranial 
and spinal ganglia. More than 95% of all German adults are VZV immunoglobulin G (IgG) 
antibody positive121. Upon a decrease in cell-mediated immunity, the virus can be reactivated 
decades later and manifests as herpes zoster (shingles)122. The lifetime risk of the 
development of an HZ episode is estimated to be 33% and increases considerably with 
age123,124. 
There are different manifestations of HZ depending on the affected dermatome. The thorax is 
mostly affected (50–56% of cases), followed by the face (20% of cases). Other neurological 
manifestations are, e.g. zoster encephalitis, zoster meningitis or HZ with other neurological 
system involvements125. In addition, there are also various HZ-related complications. The 
main complication of HZ is PHN, which occurs in 10–20% of HZ cases, but predominantly in 
patients older than 60 years126,127. It is defined as a long-lasting, occasionally recurring pain 
for 1–3 months after the HZ-related onset rash128. Another serious complication of both, 
primary infection (chickenpox) and VZV reactivation (shingles) is ischemic and hemorrhagic 
stroke, which occurs by VZV vasculopathy and affects both immunocompetent and 
immunocompromised individuals129. VZV is thought to spread transaxonally along afferent 
nerve fibers from the cranial nerve ganglia to arteries of the anterior or posterior cerebral 
circulation causing inflammation, thrombosis and occlusion of the vessels. In addition, VZV 
vasculopathy can lead to transient ischemic attacks, arterial ectasia, aneurysm and 
subarachnoid hemorrhage.  
The risk of developing HZ, its manifestations or HZ-related complications, e.g., PHN or 
vasculopathy, is increased in older and immunocompromised individuals. Systemic antiviral 
therapies are necessary and should be used as early as possible after the onset of 
symptoms. Especially in these population groups, the current pharmacological treatment 
options of HZ-related complications are challenging as they might lead to higher complication 
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rates130. Hence, to boost the VZV-specific cell-mediated immunity, a live attenuated VZV 
vaccine against HZ has been developed. However, to date (March 2018), STIKO has not 
recommended routine VZV vaccination with the live attenuated VZV vaccine based on their 
scientific evaluation of safety, efficacy and effectiveness data131,132. Furthermore, there is 
also an inactivated vaccine against HZ, which could also be administered to 
immunocompromised persons, but the vaccine has not yet been approved by EMA. Given an 
aging population and the fact that more than 95% of the German population is infected with 
VZV, the disease burden of HZ infection is supposed to increase.  
2.1.1 Incidence of Herpes Zoster and its Complications  
OA1 Incidence of herpes zoster and its complications in Germany, 2005-2009. 
Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Journal of Infection 
2014; 70(2):178-186. [https://doi.org/10.1016/j.jinf.2014.08.018] 
Methods: In this burden of diseases study, we estimated incidence rates (IRs) of HZ, its 
manifestations and complications overall, by age, sex and immune status to extend the data 
on the burden of HZ disease. The proportion of PHN, hospitalizations, the diagnosing 
physician specialty and systemic antiviral therapy were also assessed. Based on 
administrative claims data from 2005–2009, a retrospective cohort study including 7 million 
statutory health insurance members was conducted.  
Results: Between 2006 and 2009, the annual standardized IRs ranged between 5.3 and 5.5 
per 1000 person-years (PY). Females had higher IRs than males throughout the study 
period. IRs increased more than threefold (up to 15 per 1000 PY) in the age group 80–84 
compared to those 10–44 years of age. About 72% of HZ patients had no complications in 
2009, while about 16% suffered from nervous system involvement. During the other 
respective study years, these numbers were similar. The age-related increase of IRs was 
higher for HZ complications than for uncomplicated HZ. Immunocompromised patients 
suffered slightly more complications than immunocompetent patients. The annual PHN 
proportion among HZ cases increased from 12% in 2005 to 15% in 2009 with a steady age-
related elevation for both sexes. About 3% of HZ cases were hospitalized. More than 50% of 
HZ cases were diagnosed by general practitioners (GPs) and 71% of HZ cases received 
systemic antiviral treatment.  
Conclusion: The presented baseline data contribute to an enrichment of empirical data on 
the burden of HZ disease. Furthermore, these data can be used for future vaccine impact 
studies.   
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2.1.2 Risk of Stroke after Herpes Zoster Infection 
OA2  Risk of Stroke after Herpes Zoster- Evidence from a German Self-Controlled 
Case-Series Study.  
Schink T, Behr S, Bricout H, Thöne K, Garbe E. PloS One 2016; 11(11): e0166554. 
[https://doi.org/10.1371/journal.pone.0166554]  
 
Methods: To assess the risk of stroke as a serious complication after HZ onset, we 
conducted a self-controlled case-series study on a cohort of patients with incident stroke. 
Furthermore, potential differences in risks between stroke subtypes (ischemic and 
hemorrhagic) and HZ location, as well as throughout different time periods between HZ onset 
and stroke were investigated. We used administrative claims data of the years 2004–2011 
including 7.7 million statutory health insurance members.  
Results: Within the cohort of 124,462 stroke patients, 6,035 (5%) had at least one HZ 
diagnosis identified either as a main hospital discharge diagnosis or as HZ treated with 
antivirals. In the three-month risk period after HZ onset, the risk for stroke was about 1.3 
times higher compared to control periods (Incidence rate ratio (IRR): 1.29; 95% confidence 
interval (CI): 1.16–1.44). This was similar in magnitude for ischemic and unspecified stroke. 
The risk of hemorrhagic stroke was 1.5-fold higher compared to control periods. During the 3 
months after herpes zoster ophthalmicus (HZO) onset, the effect on the risk of stroke was 
slightly higher, with an about 1.6 times higher risk compared to control periods (1.59; 1.10–
2.32). During short-time periods (3–4 weeks after HZ onset), the risk for stroke was highest 
and decreased thereafter. 
Conclusion: Our study found an increased risk of stroke after HZ with highest risk estimates 
3–4 weeks after HZ onset. Stroke risk was slightly higher after HZO and was also higher for 
hemorrhagic stroke than for ischemic or unspecified stroke. 
2.2 Preventive Public Health Interventions: Vaccine Uptake and Vaccine Impact 
Studies (Using the Example of the Human Papilloma Virus) 
HPV infections are the most frequent sexually transmitted viral infections worldwide affecting 
both, men and woman133. They can result in malignant cancer or benign skin and mucosal 
tumors, including AGWs. More than 120 HPV types have been identified of which more than 
40 affect mostly anogenital epithelium. HPV types 6 and 11 account for about 90% of AGWs; 
HPV types 16 and 18 are responsible for 70% of all cervical cancers as well as for a large 
proportion of other anogenital cancers134. In 2006, a quadrivalent vaccine against HPV 6, 11, 
16 and 18 was approved by the FDA in the United States and EMA/CHMP for the prevention 
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of cervical cancer. In Germany, the HPV vaccination has been recommended for girls 
between 12 and 17 years of age by STIKO since March 2007 and since 2014, for 9-year-old 
to 14-year-old girls. The vaccine is free of charge for this age group. Additionally, some SHIs 
offer reimbursement for women aged 18–26 years. The bivalent vaccine against HPV types 
16 and 18 (recommended since March 2007) as well as the nonavalent HPV vaccine against 
6, 11, 16, 18, 31, 33, 45, 52, and 58 (recommended since April 2016) are also available in 
Germany, but to date the quadrivalent HPV vaccine strongly dominates the German 
market135. However, in 2017, the quadrivalent HPV vaccine was replaced with the nonavalent 
HPV vaccine.  
HPV vaccine efficacy was estimated to be 90–100% for preventing persistent and incident 
HPV infections as well as AGWs136. To date, the follow-up time has been too short to 
estimate protection against cervical cancer, but AGW incidence rates can be an effective 
measure for earlier outcomes of HPV vaccine impact, as AGWs develop rapidly after HPV 
infection.  
Recent studies in Australia, Europe and the United States reported an AGW incidence 
reduction of up to 90% in the vaccine-recommended age group26. Some studies also 
reported decreasing incidence in older age groups of females as well as in males, suggesting 
effects of herd immunity74,137. This would dependent on vaccine coverage and as most of 
these studies were conducted in countries with high vaccine coverage of 70% to 90%, almost 
no data on herd immunity effects are reported in countries with low vaccine coverage72–74.  
HPV vaccine uptake in Germany when based on at least one vaccine dose was low in 2008 
(about 32.2% in 12- to 17-year-old females)138. In 2012, a similarly low vaccine uptake was 
reported ranging from 6.1% in 12-year-old females to 47.6% in 16-year-old females139. 
Compared to numbers of other countries with implemented HPV vaccination 
programs/schedules these numbers are low. Reasons for a limited vaccine uptake might be 
controversial discussions on vaccine effectiveness and safety which may have led to 
uncertainty among young women, their parents or also among physicians140. Furthermore, a 
school-based vaccination program which has led to higher vaccination rates in other 
countries is still missing in Germany.  
2.2.1 HPV Vaccine Uptake in Germany 
OA3  HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of 
administrative data.  
Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E. Human 
Vaccines & Immunotherapeutics 2014; 10(6):1729-33. 
[https://doi.org/10.4161/hv.28450] 
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Methods: To assess the HPV vaccine uptake in 2008 for females aged 12–26 years on a 
broad regional level in Germany, we conducted a retrospective cohort study with data from 
one large SHI including about 7 million statutory health insurance members (about 8.5% of 
the German population).  
Results: The overall study population consisted of 317, 234 females, of whom 77,350 
received at least one HPV vaccine dose in 2008. Vaccine uptake was 32.2% in the 
recommended age group of 12- to 17-year-old females and peaked at the age of 14–16 
years (36.4%). Among older females aged 18–26 years, the HPV uptake was only 12.3%. 
HPV vaccination was not officially recommended by STIKO for this age group but the SHI 
which contributed data for this study offered reimbursement of the HPV vaccine also for this 
age group. In four federal states, about 66% received the vaccine in the recommended age, 
while about one third (33.9%) received the vaccine at older ages (18–26 years). Other states 
could not be investigated due to a lack of specific EBM codes for reimbursement of vaccine 
within this age group.  
Conclusion: The HPV vaccine uptake in 2008 reflects an early status of HPV vaccine 
uptake after vaccine recommendation in 2007. For timelier monitoring, information on future 
changes in HPV uptake is needed. This will create a basis for prompt public health reactions 
and for efforts to adapt immunization programs adequately.  
2.2.2 HPV Vaccination Herd Immunity Effects for Anogenital Warts  
OA4  Evaluation of vaccination herd immunity effects for anogenital warts in a low 
coverage setting with human papillomavirus vaccine – An interrupted time 
series analysis from 2005 to 2010 using health insurance data. 
Thöne K, Horn J, Mikolajczyk R. BMC Infectious Diseases 2017; 17(1):564. 
[https://doi.org/10.1186/s12879-017-2663-7] 
 
Methods: With this vaccine impact study, we assessed potential vaccination herd immunity 
effects among males in a German low HPV vaccine coverage setting. A retrospective open 
cohort study with data from one large SHI including more than 9 million statutory health 
insurance members from 2005–2010 was conducted.  
Results: About 5 million insurance members aged 11–79 years were included in the cohort 
for each study year. Overall, 49,214 incident AGW cases were identified. Overall incidence 
rates of AGWs were relatively stable throughout the study years. In all age groups, between 
the 1st quarter of 2005 and the 2nd quarter of 2007 incidence was approximately stable. 
Among 16- to 26-year-old females and 16- and 18-year-old males, incidence decreased 
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between the 2nd quarter of 2007 and the 4th quarter of 2008. Afterwards, the incidence 
stabilized at a lower level. In most other age groups, the incidence was relatively stable or 
increased slightly over the studied period. The incidence rate ratio of AGWs for the post-
vaccination period (2009–2010) compared to the pre-vaccination period (2005–2007) 
showed a u-shaped decrease among the 14- to 24-year-old females and also among males 
which corresponds well with the reported HPV vaccination uptake in 200871. Within the 16- to 
20-year-old females, a reduction of up to 60% was seen while for the 16- to 18-year-old 
males, a reduction of up to 50% was observed. In younger females of 21–26 years of age, a 
reduction of 10–20% was seen. This was also found for males but estimates did not achieve 
significance. The reduction in the youngest age group of 12- to 15-year-olds was about 20–
30% but with wide confidence intervals. 
Conclusion: The slightly less pronounced relative reduction among males in approximately 
the same age group as females who received the HPV vaccination suggests herd immunity 
resulting from assortative mixing by age. However, the early decrease among males may be 
reduced over time due to partner change.  
2.3 Nested Case-Control Study Design with Risk-Set Sampling (Using the Example 
of Non-Steroidal Anti-Inflammatory Drugs) 
The nested case-control design is a method that consolidates advantages of both, a case-
control study and a cohort study where cases and controls are sampled from a pre-defined 
cohort97,141. For each case, the risk-set is defined and one (or more) controls are randomly 
selected from each risk-set. This study design is sometimes used in vaccine effectiveness 
and safety studies, which will be described in detail within the discussion chapter 3.1.2. 
Within this thesis, the nested case-control design has been applied in the context of a drug 
safety study, the content of which will be shortly described in the following. 
NSAIDs are among the most frequently used therapeutics in the general population142. They 
have a wide range of clinical indications, e.g. short- or long-term pain states, fever and a 
range of chronic inflammatory and degenerative joint diseases such as rheumatic arthritis 
and osteoarthritis143. For cyclooxygenase-2 (COX-2) selective NSAIDs, an increased risk of 
adverse cardiovascular events has been reported, resulting in the withdrawal of rofecoxib in 
2004144 and valdecoxib in 2005145. Consequently, COX-2 selective NSAIDs are 
contraindicated in the EU for patients suffering from coronary heart disease, cerebrovascular 
disease and peripheral arterial disease146.  
During the last decade, several European147,148 and international149,150 observational studies 
as well as meta-analyses151–153 indicated an elevated risk of AMI for both traditional NSAIDs 
(tNSAIDs) and COX-2 selective NSAIDs. Several studies support findings that tNSAIDs may 
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increase the risk of heart failure or stroke in patients with or without heart disease or risk 
factors for heart disease143,154. However, estimates of the increased risk varied and little is 
known about the cardiovascular risk profile of tNSAIDs and COX-2 selective NSAIDs as well 
as the influence of concomitant drug use or co-morbidities. 
 
OA5  Non-steroidal anti-inflammatory drug use and the risk of acute myocardial 
infarction in the general German population: a nested case-control study. 
Thöne K, Kollhorst B, Schink T. Drugs- Real World Outcomes 2017; 4:127–137 
[https://doi.org/10.1007/s40801-017-0113-x] 
Methods: A case-control study nested in a cohort of 3,476,931 new NSAID users of the 
years 2004–2009 was conducted. Population-based AMI risks for individual and widely used 
NSAIDs, for the cumulative amount of NSAID use and for patients with and without a prior 
history of cardiovascular risk factors were estimated. Cohort members had to be 
continuously insured for at least 12 months before the first NSAID dispensation. In order to 
include only incident NSAID users, only patients without any NSAID prescription within these 
12 months were included in the cohort. Cohort entry was the first NSAID dispensing date 
between 2005 and 2009. All patients were followed from their first NSAID dispensation in the 
study period until either interruption of insurance status for more than 3 days, termination of 
insurance including death, diagnosis of malignant cancer or the end of the study 
period/longest available follow-up in the database, whichever came first. All patients with a 
first hospitalization with a main discharge diagnosis of AMI or subsequent MI were identified 
as cases. The hospital admission day was defined as the index date of the case. Up to 100 
controls were randomly matched by age, sex, SHI and length of follow-up using risk-set 
sampling. Length of follow-up was defined by assigning an index date to each control that 
resulted in the same duration of follow-up as the corresponding case. Patients might have 
served as controls for more than one case and were eligible to be selected as controls until 
they became a case. Exposure status was classified into current, recent or past users, where 
past users were used as reference. Multivariable conditional logistic regression was applied 
to estimate ORs and 95% CIs. Duration of NSAID use was calculated by the cumulative 
amount of dispensed DDDs and stratified analyses were conducted for potential effect 
modifiers.  
Results: Overall, 17,236 AMI cases were matched to 1,714,006 controls. For the most 
frequently used NSAIDs, ibuprofen and diclofenac, a 40–50% increased risk of AMI (1.54, 
1.43–1.65 and 1.43, 1.34–1.52, respectively) was observed. No association was seen for the 
COX-2 selective NSAIDs celecoxib and lumiracoxib but the number of current users was low 
and both confidence intervals included the null value. A low cumulative NSAID amount was 
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associated with a higher AMI risk for ibuprofen, diclofenac and indometacin. The risk 
associated with current use of diclofenac, fixed combinations of diclofenac with misoprostol, 
etoricoxib or ibuprofen was highest in the younger age group (<60 years) and similar for 
patients with or without major cardiovascular risk factors.  
Conclusion: Among the 15 investigated individual NSAIDs, relative AMI risk estimates 
differed. The most frequently used NSAIDs—diclofenac and ibuprofen—were associated with 
a 40–50% increased relative risk of AMI, even for low cumulative NSAID amount. The 
relative AMI risk in patients with and without cardiovascular risk factors was similarly 
elevated.
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3 METHODOLOGICAL ISSUES 
As described in chapter 1, observational studies provide important methods to assess, e.g., 
the burden of vaccine-preventable diseases and their complications, to evaluate direct 
vaccination effects (e.g., vaccine effectiveness), indirect vaccination effects through herd 
immunity or the safety of vaccines in a real-world setting.   
To investigate these different research topics, several study designs can be used, while the 
preferred design is always dependent on context and data source 155. For example, cohort 
studies, case-control studies and case-only designs are commonly used for studies either on 
the burden of vaccine-preventable disease, for vaccine effectiveness and for vaccine safety 
assessment156. While nested case-control studies are also sometimes conducted to 
investigate direct vaccination effects and safety issues, vaccine impact can be best 
evaluated by using an ecologic time-trend study design with a segmented regression 
analysis. Furthermore, based on the underlying data source each design has advantages 
and disadvantages for the investigation of the respective research questions. However, each 
design differs in terms of its susceptibility to confounding and bias.  
In this section, methodological aspects for studies on vaccines with regard to the underlying 
administrative data source will be discussed. First, the different study designs and analyses 
that were applied within the individual research articles included in this thesis are introduced 
and discussed with respect to their advantages and disadvantages (chapter 3.1). Second, 
examples of bias and confounding that might have occurred and that were addressed within 
the studies are discussed (chapter 3.2).  
3.1 Study Designs and Analyses  
3.1.1 Cohort Studies 
Cohort studies are a valuable tool in order to investigate, e.g., vaccine-preventable disease 
burden, vaccine effectiveness or vaccine safety issues.  
The general principle of a cohort study is to classify disease-free cohort members according 
to their exposure status (e.g., vaccination or no vaccination, dose schedules of vaccination 
(fully vs. one (or two) doses) or different brands of vaccines) and to follow them over time in 
order to examine the frequency of first (incident) outcome occurrence (e.g., vaccine-
preventable target disease, AVR)157.  
Depending on the follow-up time in relation to the point in time when the study is conducted, 
cohort studies can be classified into prospective (concurrent) or retrospective (non-
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concurrent or historical) studies. A retrospective cohort study can be assembled from data of, 
e.g., administrative claims data in the past and followed-up to the present (or the longest 
available follow-up). While a single-arm cohort study is sufficient to estimate incidences21, a 
multi-arm cohort study is necessary for risk estimation. In a matched cohort study, patients 
are paired by specific baseline characteristics (e.g., age, sex) but with different exposures 
(e.g., vaccination vs. no vaccination or vs. different vaccines of the same type of vaccine).  
To conduct a cohort study based on administrative data, it is important to correctly define the 
study population (the denominator) by a set of inclusion and exclusion criteria. For example, 
in order to investigate only incident cases during the observation period, a prior pre-defined 
observation baseline period must be free of diagnoses of the disease of interest. The length 
of the pre-observation period is usually chosen depending on the etiology of the disease to 
avoid misclassification of prevalent cases as incident ones (chapter 3.2.2).  
An open population is dynamic, which is often the case for cohort studies based on 
administrative claims data, where individuals enter and exit the cohort at different points in 
time (Figure 3).  
 
Figure 3: Cohort time contributed by 9 cohort members in an open cohort study (subjects enter 
and exit at different times, numbers behind bars indicate the person-time in years).  
Due to the population dynamic, it is of great importance to exactly define and assess cohort 
entry and exit dates for all cohort members in order to calculate the individual person-time at 
risk. Cohort entry of a cohort study based on administrative data can be defined as either a 
freely selected date in time, a specific age158 or the exact date of a specific diagnosis, drug 
prescription or vaccine administration97. The exit of a cohort terminates the end of follow-up 
within the cohort and thus the contribution of person-time at risk and is usually defined as the 
end of the study period, the occurrence of the outcome of interest or the end of follow-up due 
to the end of the insurance membership including death (Figure 3). In the open cohort 
studies included in this thesis21,81, patients were included if they had at least 12 months of 
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continuous insurance time during the study period and no diagnosis of the target disease 
within the 12 months prior to cohort entry. This way, only incident cases were included. In the 
HZ-study21, for HZ and its complications, incidence rates were calculated based on person-
time at risk that ended with the first respective HZ or its complication diagnosis. However, for 
descriptive purposes of the ascertainment of HZ treatment and PHN complication following 
HZ, the follow-up of HZ cases continued beyond the first day of an HZ episode to identify an 
additional PHN diagnosis or a prescription of a pain medication during the quarter of the HZ 
diagnosis or the following quarter indicating treatment for PHN and thus to capture all 
possible PHN cases. Consequently, for PHN, the proportion was calculated and not based 
on person-time.     
Based on the cohort entry and exit definitions, a cohort re-entry after a pre-defined disease-
free period is sometimes possible in order to re-enter the cohort as a disease-free cohort 
member, which is often used for vaccine-preventable diseases that have a short latency and 
a possibility for relapse. This was also the case in the HZ-study21, where a cohort re-entry 
after a repetitive diagnosis-free interval of 12 months after an HZ diagnosis was possible in 
order to capture all incident HZ cases within the cohort.  
To estimate incidence rates in open cohort studies based on administrative data, the 
numerator is defined by counting the incident number of cases in the cohort within a given 
interval of time. The denominator for the incidence rate is defined by the person-time at risk 
which is a more exact definition as it accounts for the length of time each cohort member 
spent in the population at risk of disease occurrence.  
Using administrative claims data presents specific challenges for conducting retrospective 
cohort studies. Due to the dynamic of the underlying insurance collective in GePaRD, where 
the insured persons may end or interrupt insurance or switch SHIs, left and right truncation of 
the data occurs. This is relevant for the denominator definition and consequently can best be 
taken into account by estimating incidence rates. Furthermore, diagnosis and procedure data 
are generally available in GePaRD, but only from 2004 onwards, resulting in a left truncation 
of the data, which hampers obtaining a complete history of previous diseases or medication 
intake. This is especially important in order to identify prevalent cases within a defined pre-
observation period and to exclude them from entering the cohort. The challenge of 
preventing such outcome misclassification resulting in overestimation of the disease 
incidence, was addressed in the HZ-study21 and will be discussed in more detail in chapter 
3.2.2.  
The cohort study design (as well as RCTs) is the only design that facilitates direct 
measurement of risks based on person-time. For example, the incidence rate ratio (incidence 
density ratio) as a measure of the relative risk is directly estimated by the ratio of the 
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incidence rate in the exposed group to the incidence rate in the unexposed group159, which 
are important estimates, e.g., for benefit-risk evaluation in vaccine safety studies160.  
Incidence rates of vaccine-preventable diseases often vary by age, sex, season or calendar 
year. When incidence comparisons need to be conducted, it is often necessary to calculate 
stratified or weighted incidence rates instead of only investigating crude incidence rates161. 
These methods imply that the contribution of the cohort members to the numerator and 
denominator needs to be assigned to the respective stratum. For example, in the HZ-study21, 
we estimated yearly age- and sex-adjusted standardized incidence rates (SIRs) using direct 
standardization referring to a common standard population, which will be valuable when e.g., 
a comparison with future incidence rates becomes necessary. SIRs can be also used to 
compare incidences between, e.g., years, geographical regions, immune status or specific 
time periods, in order to investigate if a specific vaccine is particularly needed in a target 
population or subgroup15. Another example for the comparison of event rates against reliable 
data from other sources is the GePaRD mortality validation study162. Here, age- and sex-
standardized mortality rates (direct standardization) in GePaRD were compared to mortality 
rates from the German Federal Statistical Office. The results showed that death is reliably 
recorded in GePaRD. Some detected discrepancies may be attributable to differences in the 
socioeconomic status of the SHI study population in comparison to the total German 
population162. 
A major advantage of retrospective cohort studies based on administrative data is that they 
are well suited to investigate the association of a rare exposure (e.g., specific vaccines) on 
one or multiple outcomes159. Due to the temporal framework of this study design, an 
association between exposure and incidence of an outcome could indicate possible 
causality157. 
Furthermore, based on administrative claims databases retrospective cohort studies offer the 
opportunity to include a large cohort sample size with a potentially long follow-up over 
several years that facilitate incidence estimation usually with sufficient power even for rare 
events/AVRs18,163. 
However, due to the enormous data size needed, a disadvantage of cohort studies based on 
administrative data compared to other observational study designs is the very complex and 
challenging data analysis. For example, to estimate absolute and relative risks, both, the 
numerator and denominator and also confounding factors need to be measured. To achieve 
this, the whole cohort needs to be enumerated and kept under surveillance to identify the 
outcome during follow-up, which becomes especially costly and challenging in the case of 
time-variant exposure and covariate status65. Furthermore, differences between exposure 
groups (e.g., vaccinated and non-vaccinated cohort members) by, e.g., socioeconomic 
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status, frailty or healthcare-seeking behavior are difficult to control in cohort studies based on 
administrative data and can lead to biased estimates (chapter 3.2.1).  
3.1.2 Nested Case-Control Studies 
In a nested case-control study based on administrative data, the selection of cases 
(individuals with the disease) and controls (individuals without the disease) is usually 
sampled by using risk-set sampling from a prior well-defined cohort (source population) with 
a known sample size that is mostly defined by similar characteristics, e.g., geographical area, 
birth year, (new) drug/vaccine users164. As differences in the odds of the preceding exposure 
(e.g., vaccination or no vaccination) can be investigated159, this is an important and valuable 
epidemiological study design which is sometimes used for vaccine effectiveness158,165,166 or 
safety studies49,167–170.   
To design a nested case-control study based on administrative claims data generally 
requires four steps: (i) the cohort needs to be defined with inclusion and exclusion criteria as 
well as with specific cohort entry and exit dates as explained for cohort studies. In our 
NSAID-study62, cohort entry was defined as the patient’s first dispensation of an NSAID (new 
user cohort). Interruption of insurance status for more than 3 days, end of insurance 
including death, diagnosis of malignant cancer or the end of the study period/longest 
available follow-up in the database, whichever came first were defined as cohort exit criteria. 
We used this design to include only new NSAID users in the cohort as the potential risk of 
AMI has been suggested to be higher soon after NSAID use than during long-term use.  
Furthermore, the primary time axis of the cohort needs to be defined which can either be 
calendar time or follow-up time.  
By using calendar time as time axis, cohort members are ranked chronologically according to 
their date of cohort entry (e.g., date of first vaccination in a user cohort), which is therefore 
called a variable-entry cohort.  
The time axis defined by follow-up time could be based on disease duration or 
drug/vaccination exposure (e.g., follow-up time since first vaccination). For example, in the 
NSAID-study62, cohort members were ranked with regard to the duration of follow-up time 
between exposure (first NSAID use) and outcome in the study (diagnosis of AMI) (fixed-entry 
cohort) (Figure 4a). 
The next step is (ii) to select all cases in the cohort at first outcome occurrence. This is 
different from cohort studies, where cohort members are included based on the presence or 
absence of the exposure. In an ideal nested case-control study, the cases are the same 
individuals that would have been identified as cases in the respective cohort study of the 
same population171. To select eligible controls, the third step is (iii) to define the risk-set of 
possible controls for each case. The risk-set consists of all cohort members who are at risk of 
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developing the outcome at the date of the outcome occurrence of the respective case (index 
date), meaning they are disease-free members of the cohort at that index date. Finally (iv), a 
predefined number of controls are randomly selected from each risk-set (risk-set sampling)97. 
In the NSAID-study62, up to 100 controls from the cohort of new NSAID users were randomly 
selected for each case and matched by age at index date, sex and SHI using risk-set 
sampling which can be also applied in vaccine studies. By the definition of risk-sets, cases 
and controls have the same index date resulting in the same duration of follow-up and 
individuals might serve as controls for more than one case and are eligible to be selected as 
controls until they become a case172 (Figure 4b). 
 
Figure 4a: Illustration of a fixed-entry cohort ranked chronologically by follow-up time, with 
new risk-sets for the four cases (modified from Suissa 2006, Textbook of 
Pharmacoepidemiology173). Figure 4b: Nested case-control sample of one control per case 
from the cohort in Figure 2 using risk-set sampling (modified from Suissa 2006, Textbook of 
Pharmacoepidemiology173).  
This approach is similar to that in a cohort study, where a case contributes to both, the 
numerator and denominator for incidence estimation. In the NSAID-study62, cohort members 
who were hospitalized for any reason at the index date of the case were excluded from the 
set of potential controls, since they were not at risk of being hospitalized because of an AMI 
event.  
With the sampling technique in this more modern epidemiological study design, practically 
the same results for measuring exposure-outcome associations can be achieved as with 
cohort studies. The matching is accounted for by the statistical analysis, which uses 
conditional logistic regression to provide OR estimates. The risk-set sampling has the 
advantage that the resulting OR is an estimator of the relative risk (incidence rate ratio)—that 
is directly measured in cohort studies—without the necessity of the “rare disease 
assumption”171, as the exposure odds of the cases divided by the exposure odds of the 
controls approximate the incidence rate ratio of the source population171.  
For administrative database studies, the nested case-control design offers several 
advantages. A major advantage is that the exposure assessment (e.g., vaccination status at 
the time of the event) is only necessary for cases and matched controls and not for all cohort 
members65. This is more cost- and time-efficient97 compared to the enumeration of a 
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complete cohort while the analysis has nearly all the statistical power of traditional cohort 
studies157,171. Another advantage of a nested case-control study is that the calculation of 
person-time is only needed for the identification of the index date of the cases and controls 
for risk-set sampling and not for the entire cohort. Furthermore, vaccinated and unvaccinated 
population groups often differ by further characteristics, e.g., frailty, health status or 
healthcare-seeking behavior174. The possibility to assess more easily information on 
confounding variables within pre-defined time window(s) before the index date compared to 
the complete follow-up time in a full cohort study is another advantage of the sampling 
technique. Therefore, it is also more practical to assess time-variant confounders or time-
variant exposure status with different start and end dates than in cohort studies. While in a 
full cohort analysis, all cases and controls are necessary for analysis97,175, in a nested case-
control study, only a random sample is required. For example, in the NSAID-study62, potential 
confounders (comorbidities) were assessed in the 12 months before cohort entry and drug 
use was determined in the 12 months or 90 days before index date. Classification of 
exposure status of NSAID use was based on the period (in days) between the index date 
and the end of supply of the most recent dispensing before the index date based on the 
DDDs. The user status at the index date was then categorized as current, recent or past use 
(defined as reference) for cases and controls.  
Furthermore, the identification of eligible controls from the cohort in which the case-control 
study is nested is relatively straightforward and reduces the potential for selection bias97,156 
as the well-defined underlying cohort (e.g., birth cohort, new user cohort), that is mostly 
defined by similar characteristics is the source of both, cases and controls.  
The nested case-control design is especially useful for diseases or outcomes that are 
relatively rare yet their investigation is of vital importance65 (e.g., target diseases after highly 
efficacious vaccines, AVRs after vaccination). It is also more efficient than a cohort study for 
diseases with long latency or induction periods.  
The major disadvantage of nested case-control studies is that they are generally inefficient 
for the investigation of rare exposures and are limited to one outcome under investigation. In 
turn, the nested case-control design facilitates the simultaneous evaluation of multiple risk 
factors for the outcome of interest176.  
However, a study96 based on GePaRD investigating the occurrence of an AVR, i.e., febrile 
convulsion within a pre-specified individual risk window shortly after exposure to different 
brands of childhood vaccination (MMR, MMR+V, MMRV) has been conducted as a matched 
cohort study which might be sometimes a more appropriate study design because the 
exposure risk window can be defined better than in a nested case-control setting where a 
“look-back period” needs to be defined for both cases and controls.  
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Without information on important confounding factors in the database, it is impossible to 
conduct vaccine safety or effectiveness studies based on administrative data which is the 
case for influenza vaccine effectiveness with respect to frailty bias (chapter 3.2.1). 
Consequently, alternative study designs have to be applied which will be discussed in the 
next chapter. 
3.1.3 Case-Control Studies 
In traditional case-control studies, the key challenge is the sampling/matching of the controls 
from the source population independently of their exposure status. The controls should 
provide an estimate of the distribution of exposure and covariates in the source population 
leading to the cases, in order to exploit the benefits of a case-control study over a cohort 
design171. In contrast to a nested case-control study, a traditional case-control study samples 
cases and controls usually from a source population of unknown size and without similar 
underlying characteristics.  
It is not possible to estimate exposure-specific incidence rates in traditional case-control 
studies177, which is in contrast to nested case-control studies (chapter 3.1.2). However, if the 
disease under investigation is rare—which is usually the case in case-control studies—ORs 
are a close estimate of the relative risk159.   
Both, case-control studies and nested case-control studies may be less efficient whenever 
vaccine safety or effectiveness within populations with a very high or low vaccination 
coverage (e.g., <10% or >80%, respectively) is investigated49. For example, in settings with 
high vaccine coverage and high vaccine efficacy, a decline of the target disease might 
represent a major challenge for the sampling of an efficient number of suitable cases to 
investigate vaccine effectiveness with enough precise statistical power and would probably 
require an increase of the sample size65. Furthermore, in this scenario, unvaccinated 
individuals might differ from the vaccinated ones and consequently from the general 
population in several characteristics that might be associated with the outcome, 
independently of vaccination65. Then, a person-time analysis from a cohort might provide 
more valuable information.  
Compared to the nested case-control design, a traditional case-control study is more prone 
to selection bias as cases and controls might differ in several characteristics as they are not 
sampled from a pre-defined underlying cohort by using risk-set sampling.  
Matching in case-control studies is intended to control for confounding and to gain efficiency 
compared to cohort studies178,179. This thesis discusses the case-control design in order to 
explain the test-negative design as an alternative study design to conduct an influenza 
vaccine effectiveness study which is not possible in GePaRD.  
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The test-negative design (TND)  
Cohort, nested case-control and case-control studies based on administrative data 
investigating, i.e., influenza vaccine effectiveness—a vaccine that is recommended for older 
patients or for patients with comorbid conditions180—are particularly vulnerable to selection 
bias, namely frailty bias which could lead to a healthy vaccine effect181,182 (chapter 3.2.1). 
Furthermore, the potential mismatch of the seasonal, circulating viral strain with the antigens 
in the vaccine increases the complexity of influenza effectiveness studies.  
The test-negative design (TND), which shares some similarities with the case-control design, 
has been suggested as a more valuable design for the investigation of the influenza vaccine 
effectiveness in order to reduce frailty bias183. In a case-control study, cases are sampled 
based on the disease occurrence and controls are usually sampled based on the absence of 
the disease. In a TND, the selection for inclusion in the study occurs before the case status is 
known but only from the group of individuals seeking medical care for symptoms of, e.g., an 
acute respiratory illness (ARI)183. The patients are not defined as cases until they are tested 
for laboratory-confirmed influenza. Those who are tested negative are defined as controls. In 
principle, within the TND the vaccine status between influenza test-positive cases and test-
negative controls who all sought medical care for an ARI is compared by calculating vaccine 
effectiveness adjusted for potential confounders184.    
The TND is only applicable if the data source includes information on influenza test and 
vaccination status or if the required information can be obtained by linkage to other 
datasets185. Unfortunately, laboratory data are usually not available in administrative 
databases and specifically not in GePaRD. Furthermore, there are several other factors that 
can affect the vaccine effectiveness, like virus and host factors, prior exposure to the 
disease, waning of efficacy and boosting, addition of adjuvants, the match to circulating 
strains, the individual immune status, etc.58,186,187. Some of this information is also not 
available in GePaRD and consequently represents an additional challenge for the conduction 
of vaccine effectiveness studies based on administrative databases.  
For the estimation of influenza vaccine effectiveness, the TND has an advantage compared 
to other observational study designs mainly because it is less costly and easier to implement 
as cases and controls are recruited in one process185,188. Furthermore, the TND is reported to 
be less susceptible to frailty bias as one can assume that the test-negative patients were 
more similar to the test-positive patients in their health status and healthcare-seeking 
behavior183 as well as in their comorbidities than randomly sampled controls in traditional 
sampled case-control studies189 since controls would have been defined as cases if they had 
the outcome of interest. Furthermore, outcome misclassification of influenza is reduced as 
only patients with a positive influenza laboratory test result are defined as cases. This might 
be also different from traditional case-control studies, where controls are often defined as 
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individuals without influenza diagnosis but without confirmed test results. Furthermore, it has 
been reported that estimates of the TND were closer to RCT estimates than those generated 
with traditional observational study designs190.  
However, by using, e.g., influenza-specific study endpoints, this design presupposes that test 
sensitivity and specificity of diagnostic methods have to be high to avoid misclassification80.  
Generally, careful interpretation of vaccine effectiveness estimates is needed if a high 
vaccination coverage results in high herd immunity effects as these would increase 
protection against the viral agent among vaccinated and unvaccinated individuals by reduced 
viral transmission, which could lead to an underestimation of vaccine effectiveness191. 
Therefore, to investigate indirect vaccine effects, other study designs are more appropriate 
which will be discussed in the next chapter. 
3.1.4 Ecologic Studies 
An ecologic study compares exposure and outcome measures between populations or 
groups, rather than between individuals192. Exposure measures (e.g., vaccine introduction) 
are often aggregated measures (e.g., proportions) or global measures (e.g., densities). 
Outcomes can be mortality rates, prevalence data or, like in the HPV-impact-study81 
incidence rates of AGWs that have been stratified by populations groups, e.g., 1-year age 
groups and sex to observe potential indirect HPV vaccine effects. Also, strata of race or 
socioeconomic status are possible in ecologic studies.  
Within an ecologic study it is possible to estimate aggregated individual-level data like the 
incidence rates of the target disease at time points before vaccine recommendation and 
compare them with incidence rates and transmission rates (including the unvaccinated 
individuals) of the period after vaccination uptake was established (“before/after studies”). 
This can be done either by graphical displays and/or by segmented regression models 
(chapter 3.1.5). In the HPV-impact-study81, in order to capture all vaccination effects, 
including indirect effects, we studied changes in AGW incidence rates in a study population 
which was restricted to 11- to 30-year-old females (the target vaccination groups ) and males 
immediately following the recommendation of vaccination to investigate potential herd 
immunity effects. Therefore, two time intervals were defined: i) time before the 
recommendation of vaccination and ii) after uptake of vaccination was established.  
This study design is an important part of the evidence base for several vaccines after their 
introduction within the general population99. In contrast to other study designs, where 
different patient groups are compared at a specific point in time, an ecologic time trend study 
can be considered a valuable research method due to the longitudinal natural experiment as 
the patients are followed over time to investigate potential changes after a vaccine 
introduction193. For example, the main interest is often to investigate herd immunity effects, 
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which is a group effect rather than an individual effect and can only occur if the vaccine 
uptake is sufficiently high as explained in chapter 1.3.3.  
There are some advantages of ecologic studies. Based on administrative data, vaccine 
impact studies can be generated in a less time-consuming way in order to generate a rapid 
evaluation of the impact of a vaccine at the population level shortly after vaccine introduction. 
Furthermore, if applied to an administrative data source, this design offers the advantage of 
including very large population groups facilitating even the investigation of small changes in 
incidences or within specific subgroups of individuals. However, even in large databases 
numbers of specific strata might be sometimes too low to achieve statistical significance.  
A disadvantage of an ecologic study is that it is not possible to conduct and quantify cause-
and-effect analyses among individuals as the data are averaged measurements of groups, 
and ecologic bias (e.g., ecologic fallacy) can be introduced194. This can be interpreted as “the 
failure of ecologic associations to reflect the biological effect at the individual level”195. This 
definition also implies the impossibility of estimating confounding effects. The underlying 
problem of this ecologic bias is heterogeneity of exposure and covariates within groups that 
cannot be captured with ecologic data as information on the individual level is missing194. In 
the HPV-impact-study81, heterogeneity of the exposure level within specific age groups might 
explain observed indirect vaccination effects in older female age groups or in males despite 
quite low coverage overall. This might have occurred as vaccination is voluntary in Germany 
(although recommended) and the HPV vaccination can occur at any age from 12–17 years 
(since 2015 from 9–14 years), which is different to immunization programs where a 
percentage of girls of a certain age is vaccinated. In consequence, coverage in Germany is 
low for the full age group of 12- to 17-year-olds, but in those older than 17 years coverage 
cumulates over time as more and more women get vaccinated.Such heterogeneity might 
also explain why effects in males can be observed despite overall low coverage.  
Furthermore, results about potential causal inference within ecological studies based on 
administrative claims data can be hampered due to very long, varying or even unknown 
latency between intervention and outcome194. In the HPV-impact-study81, the incidence of 
AGWs started to decrease among the 16- to 26-year-olds approximately 3 months after the 
vaccine recommendation by STIKO in Germany in March 2007. The short delay with which 
the effects of vaccination on AGW incidence were observed is consistent with the biology of 
infection. As HPV immunity is reported already after one vaccine dose and AGWs develop 
after a medium incubation time of about 3 months, the corresponding time lag of decreasing 
incidence of 1–2 quarters of a year after the vaccine recommendation for females is 
plausible.  
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3.1.5 Segmented Regression Analysis 
For a segmented regression analysis (also called interrupted time-series analysis or 
piecewise regression), sequential and regular outcome measures are needed at equally 
spaced intervals and with a sufficient number both before and after the intervention (e.g., 
vaccination)196. Then, a time series of outcome measurements (e.g., incidence rates) can be 
used to define an underlying presumably stable time trend before the vaccine intervention, 
which is (potentially) disrupted by the vaccine introduction at a specific time point (breaking 
point)197. However, it is especially important to know the data quality in order to understand 
the potential impact of coding changes, particularly when these are introduced at the same 
time as the vaccine197. Since we investigated incidence rates of AGWs three years before 
and after vaccine introduction in the HPV-impact-study81 and observed approximately stable 
incidence rates throughout the study years as well as we were not aware of a change of ICD-
10-GM coding of the AGW outcome or other conspicuous changes in the data, an interrupted 
time-series analysis could be conducted to investigate vaccination herd immunity effects of 
AGWs based on the underlying data source.  
The study period can be subdivided by a breaking point into a pre-intervention period and a 
post-intervention period, creating segments196 (Figure 5). The impact of the intervention can 
be examined by the change in level, e.g., a change in the incidence rates occurring between 
the pre- and post-intervention period198,199 or by a change in trend defined by a change in the 
slope of the segment after the intervention compared with the segment before the 
intervention196. However, it is sometimes difficult to define the exact time point when the 
intervention began. For vaccine impact studies, a breaking point is often assumed at the time 
of vaccine recommendation/introduction. In a first analysis200, based on administrative data, a 
Poisson regression model was used that includes age, calendar time in quarters of the year, 
calendar time within one year, and calendar time in relation to the breaking point, to test all 
possible breaking points throughout the study period and to finally select the one with the 
best goodness of fit based on the Bayesian Information Criterion (BIC)201. This analysis200, 
suggesting evidence of a change in trend in the AGW incidence in the second quarter of 
2007 (HPV vaccine recommendation by STIKO) based on the lowest BIC (breaking point). 
Based on this, changes in AGW incidence immediately following the recommendation of 
vaccination were studied81,200. For example, in the HPV-impact-study81, we investigated 
stable incidence rates in all age-groups between the 1st quarter of 2005 and the 2nd quarter 
of 2007. Among 16- to 26-year-old females and 16- and 18-year-old males AGW incidence 
decreased between the 2nd quarter of 2007 and the 4th quarter of 2008 and stabilized at a 
lower level afterwards.  Administrative claims data are a reliable data source for segmented 
regression analyses, as they provide data over long time series with a high number of 
regularly assessable time points which increases the power of analysis. 
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Figure 5: An effect of vaccination observed by a decrease of outcome trends in level and slope. 
Bold black lines indicate observed rates, the dashed line indicates intervention introduction, 
the grey line indicates expected rates if the intervention had not been introduced. (modified 
from Schneeweiss et al. 2001, Health Policy202) 
However, a good understanding of the validity and reliability of the data is necessary with 
regard to the potential of misclassification (chapter 3.2.2) and confounding (chapter 3.2.3). 
One major strength of the segmented regression analysis is the fact that it is relatively 
unaffected by time-invariant confounders (e.g., socioeconomic status). Furthermore, short-
term outcomes that occur soon after intervention introduction are the most appropriate 
outcomes to measure an intervention impact as the timing between intervention and outcome 
is clearer197. For example, in the HPV-impact-study81, changes of an endpoint occurring 
earlier (AGW incidence reduction) were used to investigate vaccine impact instead of the 
primary outcome that develops slowly and requires long-term follow-up (e.g., cervix 
carcinoma which is the intended preventive goal of the HPV vaccine).  
The major advantage of time series designs is that they are valuable study designs to 
investigate a longitudinal impact of an intervention (i.e. vaccination schedule/program) or for 
the estimation of intervention effects in non-randomized settings and that they are less likely 
to generate misleading results compared to other observational study designs196.  
For example, vaccine effectiveness studies conducted as cohort, nested case-control studies 
or case-control studies do not measure the indirect effects of a vaccine introduction at the 
population level65 and are more prone to confounding owing to group differences197. 
Furthermore, other designs are not as suitable as interrupted time-trend studies for the 
investigation of vaccine impact. This is due to the fact that the dynamics of the vaccine target 
disease can be easily displayed in time-trend studies and with the design it is possible to 
control for pre-existing trends196. Furthermore, the effect size can not only be estimated at 
different time points but also as a trend over time.  
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However, as a disadvantage, it is not possible to control for individual-level covariates that 
would confound the segmented regression results196. Furthermore, in the HPV-impact-
study81, due to data protection reasons, only the birth year but not the exact date of birth was 
available in the database and some persons may already have been 1 year older according 
to the definition of age. Consequently, for the analysis of trends over time, the age of each 
patient was kept the same throughout all four quarters of the year, which led to an average 
aging cohort from the 1st to the 4th quarter of a year resulting in higher incidences in the 4th 
quarter than in the 1st quarter of each year most prominently for 16- to 20-year-olds. 
Furthermore, exact diagnosis dates in the outpatient sector are not available in the database, 
making the estimation of incidence less precise. It is not possible to control for time-variant 
confounding or to investigate that the vaccine effect actually occurred in vaccinated 
individuals (on the individual level) which might produce misleading results192. 
Besides using an ecologic design with time-trend analysis in the HPV-impact-study81, it would 
have been also possible to conduct a HPV vaccine effectiveness study as a cohort or nested 
case-control study based on administrative data under certain conditions. In this case, the 
assessment of the individual vaccination status of the target vaccination group would have 
been required. In Germany, since March 2007, the bivalent and quadrivalent HPV 
vaccinations have been recommended by STIKO for girls between 12 and 17 years of age, 
and since 2015 for girls between 9 and 14 years. The decision on which of the two available 
vaccines (bivalent or quadrivalent) should be used is jointly made by physicians and patients. 
However, the German market is strongly dominated by the quadrivalent HPV vaccine 
Gardasil® (90% of the market share)135, so that the effectiveness of Gardasil® in preventing 
AGWs could theoretically be assessed in vaccinated girls with GePaRD. But during 2007 and 
partly during 2008, uniform and specific EBM codes for HPV vaccination were not adequately 
applied. Consequently, it is difficult to exactly define the lack of Gardasil® vaccination and 
therefore the fraction of non-vaccinated females, hampering the conduction of HPV vaccine 
effectiveness studies in GePaRD for the time shortly after vaccine recommendation in 2007 
and for females older than 17 years (chapter 1.4.2). Therefore, future effectiveness analyses 
should be limited to federal states with the respective available codes for older females and 
with longer time periods of more recent years. This will provide information to clarify 
uncertainties regarding the initial introduction period of the HPV vaccine when specific EBM 
codes were not available yet. However, for the HPV-impact-study81, the impossibility to 
distinguish between the bivalent and the quadrivalent HPV vaccination as well as the fact 
that non-vaccinated females could not be exactly defined by specific EBM codes during the 
years 2007 and 2008 was not a limitation for the investigation of the impact of the HPV 
vaccine in the general population.   
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3.1.6 Self-Controlled Case-Series Design 
The self-controlled case-series (SCCS) design was primarily developed to investigate acute 
(temporary) adverse events after vaccination (transient exposure) using only data from 
cases203,204. In principle, the SCCS method compares the incidence of the outcome within a 
pre-defined risk period after exposure to the incidence of the outcome during other times 
after exposure defined as control periods97,205.   
To conduct an SCCS study for the investigation of events after vaccination based on 
administrative data, the study time windows are defined first, either by boundaries of specific 
age-ranges or calendar time periods97. The length of the study time windows depends on the 
vaccine exposure under study and its biological mechanism which might lead to the event. 
The boundaries of the study time windows should be chosen in such a manner that an 
individual can experience both, risk and control periods97. All individuals who have 
experienced an event of interest (cases) are selected. The observation period of each case 
is determined and the exact date of vaccination history is assessed97. Risk periods during the 
observation period after vaccination are defined as, e.g., a pre-defined fixed number of days 
after vaccination within which an event would likely occur. In the SCCS-study33, we 
investigated the stroke risk after an HZ infection and the beginning of the risk period was 
defined as the date of HZ onset. The end of the risk period was defined as 91 days thereafter 
since a patient was considered to have an elevated risk of stroke during this risk period. In a 
secondary analysis, the end of the risk period was further divided into intervals of 1–14 days, 
14 days to 1 month, 2–3 months, 4–6 months and 7–12 months after HZ onset to assess the 
temporal pattern of the HZ-related risk. Remaining time periods of the cases’ observation 
period (more than 12 months) were defined as control periods. Consequently, in the SCCS 
design, the entire observation period of an individual case is divided into fixed risk and 
control periods, meaning individuals act as their own controls97. The events that are regarded 
as random (e.g., stroke in the SCCS-study33) are “mapped” in relation to one of these 
different periods. Therefore, the only variability is whether the event occurs in a risk or control 
period. This information is then used to estimate the exposure effect. By using conditional 
Poisson regression the relative incidence of the outcome is estimated97,206. There are three 
main assumptions of the SCCS design: (i) events arise in a non-homogeneous Poisson 
process, (ii) the SCCS design requires both, independent recurrent events or rare non-
recurrent events and (iii) the observation period must be independent of the event date, 
meaning the outcome must not censor or terminate the observation period206. If events 
always occurred at exactly the same time or age, the SCCS design would fail as there would 
be no within-individual variation207.  
Applied to administrative databases, the SCCS design is a valuable and appropriate method 
if exact information on the denominator is lacking or difficult to be defined and it is most 
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attractive to account for all time-invariant confounders (e.g., genetic and socioeconomic 
factors) as it is self-controlled207. Furthermore, for investigating vaccine safety issues or risks 
of severe complications after an infection there may be substantial differences between 
exposure groups. As comparisons in the SCCS are made within individuals rather than 
between individuals, this is a valuable advantage. 
Based on administrative data it is challenging to investigate whether the main assumptions of 
the SCCS design are violated. In the SCCS-study33, the latter two assumptions were violated 
when a stroke resulted in death. Therefore, sensitivity analyses were conducted and patients 
with fatal strokes were excluded to evaluate the impact of fatal strokes on the study 
results206. However, the exclusion did not change the estimate of the IRRs nor the 
corresponding CIs, supporting the robustness of our results.  
Compared to cohort, case-control or nested case-control studies, the SCCS design reduces 
unmeasured and residual confounding, for which adjustment is difficult in other observational 
study designs. This was especially valuable in the SCCS-study33, since multifactorial risk 
factors that are not represented in GePaRD data can lead to stroke. However, it is often 
necessary to control for other time-variant confounders especially if follow-up time is long 
(chapter 3.2.3). This was done in the SCCS-study33 as the observation period was split into 
further time-periods to account for respective changes of confounding factors over time205.  
The SCCS design comprises some principles of a cohort study, for example, based on the 
fixed vaccination history, the individuals are followed over time until events occur (or not). 
However, unlike in a cohort study, follow-up time is not censored at the time of event 
occurrence205. 
With the SCCS design, it is also possible to use more than one risk period and to investigate 
the association between an event and multiple exposures or vice versa as well. Acute events 
and shorter risk periods relative to control periods are favored over longer and therefore 
more indefinite risk periods as these are more susceptible to confounding between, e.g., age 
(or other relevant time-variant factors) and exposure (vaccination) effects205. 
Furthermore, SCCS designs are considered suitable or even equivalent to cohort studies for 
investigating the influence of temporal, explicitly defined vaccinations on AVRs or of 
infections on acute events, but they are also considered susceptible to exposure 
misclassification (chapter 3.2.2). Thus, in administrative databases and for individuals, who 
have multiple outpatient diagnostic codes within the same quarter and/or diagnostic codes 
during hospitalization, it is difficult to determine if the outcome subordinated the exposure. It 
is therefore necessary to assess a date-specific exposure and outcome status, which was 
done in the SCCS-study33 (chapter 3.2.2).  
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3.2 General Biases 
A bias can be defined as a systematic error of an observational study design that occurred 
during the design and conduct of the study208. As it is difficult to obtain adjustment for bias at 
the stage of analysis, it is important to consider and control which bias might be introduced in 
the study in order to avoid or minimize its extend on the validity of the observational study 
results.  
There are several types of bias in clinical epidemiological studies, but most of them can be 
assigned to two major groups: selection bias and information bias. 
Within this chapter, (I) a specific type of selection bias, namely frailty bias, will be discussed. 
This bias has been reported to occur in influenza vaccine effectiveness studies conducted 
with cohort, nested case-control or case-control designs based on administrative data; (II) 
outcome and exposure misclassification will be discussed and examples of addressing this 
form of information bias within the underlying data source will be given; (III) time-variant and 
time-invariant confounding and ways to address them by using the appropriate study design 
to investigate the respective research questions will be discussed.  
3.2.1 Selection Bias 
Selection bias in descriptive studies (incl. surveys) occurs if the selection, the self-selection 
(bias due to sampling), no participation (non-response bias) or the survival (survivor bias) of 
individuals for study participation is not representative of the population that was originally 
intended to be analyzed208. Selection bias in analytic epidemiological studies (observational 
studies) based on administrative data can occur (i) due to non-representative “unexposed” 
groups of the source population, (ii) due to differential loss to follow-up among exposed and 
unexposed individuals, (iii) if the selected cases are not derived from a well-defined source 
population or (iv) if the selected controls are not providing an unbiased sample of the 
exposure distribution in the source population208,209. 
Selection bias would lead to a different exposure-outcome association in the study 
population compared to individuals who are not participating in the study but are potentially 
eligible to be included. The observed effects may then be biased by factors determining 
participation and/or outcome161.    
 
Frailty Bias 
In influenza vaccine effectiveness studies using a cohort or case-control design, selection 
bias may occur as vaccinated and non-vaccinated persons might differ with respect to 
frailty63. Frailty is defined by Fried et al. as “a biologic syndrome of decreased reserve and 
resistance to stressors, resulting from cumulative declines across multiple physiologic 
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systems, and causing vulnerability to adverse outcomes”210. This definition distinguishes 
frailty from disability or comorbidity and assessing accurate indicators of frailty is therefore 
quite difficult181.  
Because influenza vaccination is recommended mostly for the elderly or in populations with 
poor health and as vaccination is voluntary, a frailty bias occurs if patients choosing to be 
vaccinated have a better baseline health or have better health behaviors than patients not 
being vaccinated181,211,212.  
The influenza vaccine should reduce the occurrence of flu symptoms, hospitalizations for 
pneumonia and mortality193. In the presence of frailty bias, an overestimation of influenza 
vaccine effectiveness has been reported to occur in cohort or case-control studies, resulting 
in large biased reductions in all-cause mortality of ~50%165,213, while excess mortality 
attributable to influenza has been reported to be less than 10%214,215. Furthermore, several 
cohort studies not accounting for frailty bias reported less pneumonia-related hospitalizations 
for influenza-vaccinated older patients compared to non-influenza vaccinated older 
patients216–218. Accurate indicators of frailty and consequently differences regarding frailty 
between the vaccinated and non-vaccinated groups are generally hard to characterize in 
administrative databases as frailty is not captured by ICD-10-GM codes181. Consequently, 
matching or adjusting for frailty is either not possible or rather difficult.  
Therefore, the cohort, case-control or nested case-control study design using administrative 
databases for influenza vaccine effectiveness is prone to bias, especially when investigating 
unspecific outcomes (e.g., all-cause mortality, pneumonia)219. Instead, studies of alternate 
designs like the TND have been reported to be less susceptible to frailty bias in influenza 
vaccine effectiveness estimation190 as they reduce differences between vaccinated and 
unvaccinated persons during the study design phase resulting in less selection bias184 
(chapter 3.1.3).   
An area of application for observational cohort studies based on administrative database 
without the possibility to control adequately for frailty bias is the comparison of influenza 
vaccine effectiveness estimates obtained “off-influenza season” to estimates from the 
influenza season to detect frailty bias since usually no vaccine effect should be present 
during the “off-season”220. If vaccine effectiveness were detectable during this control period, 
this would indicate bias due to frailty. 
3.2.2 Information Bias 
Information bias occurs if systematic differences regarding exposure or outcome 
classification between study participants arise. Such classification errors can be introduced 
either by the observer in RCTs (observer bias), the study participant (responder bias) or by 
the measurement instruments (instrument bias). Errors in measurement itself can be defined 
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as misclassifications and can be distinguished into differential and non-differential 
misclassification221. A differential misclassification occurs if the information errors differ 
between exposed and non-exposed individuals or between cases and controls which can 
lead to an over- or underestimation of the study effects. A non-differential misclassification 
occurs if misclassification is similar between the exposure groups (in cohort studies) or 
outcome groups (in case-control studies). This happens, if the exposure is unrelated to other 
variables (incl. the outcome) or vice versa and can usually lead to bias towards the null222. 
For example, the intake of OTC pharmaceuticals (e.g., Aspirin) can only be defined as “non-
use” in GePaRD as OTC pharmaceuticals are not recorded in the database. In reality, the 
intake would need to be defined as “use” for patients obtaining it OTC.  
Therefore, the correct identification of the study outcome and the exposure status is of 
crucial importance. As administrative claims data are primarily collected for reimbursement 
purposes and comprise a dynamic structure of insured individuals, exposure and outcome 
assessments based on this data source involve specific challenges138 that will be discussed 
in the following. 
 
Outcome misclassification 
The outcome identification impacts the estimation of the disease burden or the identification 
of a disease as an outcome in effectiveness or safety studies. The aim of an accurate 
assessment of the study outcome is to avoid misclassification, e.g., to erroneously classify a 
healthy individual as “diseased” or a diseased individual as “healthy”.  
Outcome identification in administrative claims data is mostly based on the information from 
outpatient and inpatient diagnoses. This means that only diseases for which the patients 
were seeking medical care (also including chance findings [Ger.: Zufallsdiagnosen]) and 
which could be coded by a respective diagnostic ICD-10-GM code can be identified in the 
GePaRD database.  
Since 2003, inpatient diagnoses are coded by uniform coding guidelines and are generally 
used for reimbursement purposes based on diagnosis-related groups (DRGs) which combine 
the principal discharge diagnosis, diagnostic codes, and clinical procedures223. As SHIs 
cover the operating costs via DRGs, inpatient diagnoses are checked and audited regularly 
by the SHIs. Therefore, it can be assumed that inpatient diagnoses accurately reflect 
patients’ clinical conditions as well as the provided care223.  
Outpatient diagnoses depict the physician’s medical opinion at the time when care is given to 
the patient without a required laboratory confirmation of the diagnosis classification223,224. 
However, sometimes medical information and diagnoses may change during the course of 
the disease and a final reliable diagnosis can only be made if several pieces of information 
are assembled over time. To indicate the medical decision-making process, the coding of 
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outpatient diagnoses requires physicians to code diagnostic certainty with the categories 
‘certain’, ‘suspected’, ‘excluded’ and ‘status post’. In contrast to regular reviews of inpatient 
diagnoses, outpatient diagnoses are not checked regularly for coding quality as they are not 
related to the amount of reimbursement223. Therefore, there may be uncertainties regarding 
accurate diagnostic coding, and thus the validity of the information225. However, EBM and 
OPS codes are checked and audited as they are directly related to reimbursement, and 
hence give valid information on coding of in- and outpatient operations and procedures223.  
Due to German data protection regulation, it is almost impossible to validate cases against 
patient charts. However, to validly identify an outcome it has been suggested (i) to develop 
case-identifying algorithms with different sensitivity and specificity, (ii) to provide information 
on outcome misclassification, (iii) to compare event rates against external data or (iv) to build 
longitudinal patient profiles to better understand the clinical context223.  
One example for applying different outcome definitions is the HZ-study21, in which HZ 
episodes were identified via inpatient main discharge diagnoses as well as via outpatient 
diagnoses coded as ‘certain’ or with missing diagnostic certainty. In 2004/2005, coding of 
diagnostic certainty was not yet fully implemented and it has been reported that only about 
22% of outpatient diagnoses have been coded with their diagnostic certainty225. If the 
diagnostic certainty was only partly captured (from introduction until 2005) and no missing 
diagnostic certainty was included in the outcome definition, the burden of disease would be 
underestimated. On the other hand, if the diagnostic certainty was captured wrong, e.g., if a 
‘suspected’ or ‘excluded’ diagnosis was coded as a certain diagnosis, misclassification could 
be introduced and an overestimation of the incidence rates were to occur. To determine 
potential misclassification due to missing diagnostic certainty in the year 2005, a second 
outcome definition with higher specificity and lower sensitivity was introduced, that included 
not only ‘certain’ but also ‘suspected’ outpatient diagnoses for the years 2006-2009, and 
confirmed the possible overestimation in 2005 due to missing diagnostic certainties. Another 
example for the application of different outcome definition algorithms is the identification of 
PHN cases in the HZ-study21, where in addition to ICD-10-GM diagnoses, also specific 
treatment options recommended for zoster pain by the Guideline of the German 
Dermatological Society were included226. 
Because patients with chronic diseases may have regular contact with the healthcare 
system, their diagnoses are regularly coded in the data. In this case, a shorter time period 
may be sufficient to identify them as prevalent cases. For infectious diseases like HZ, a 
longer pre-observation period of one or two years is mostly chosen in order to identify all 
prior HZ diseases and to avoid misclassifying prevalent cases as incident ones. However, an 
incomplete history of the disease before cohort entry is a frequent problem within 
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administrative database studies due to left truncation of the data97 especially if the duration of 
the disease correlates with disease severity (e.g., diabetes mellitus).  
Outcome algorithms with different sensitivity and specificity have been also applied in some 
other GePaRD-based studies96,113. For example, in a study assessing the risk of febrile 
convulsion after vaccination with Priorix-TetraTM, MMR and MMR + V, one outcome algorithm 
included hospitalized cases of febrile convulsion and excluded alternative plausible causes 
which might have led to febrile convulsion (e.g., an infection or a neurologic condition) to gain 
high specificity, while the other outcome algorithm with higher sensitivity only excluded 
hospitalizations for febrile convulsion with a neurological condition as main discharge 
diagnosis96.  
In another study that investigated background incidence rates of the Guillain-Barré 
Syndrome (GBS), one outcome algorithm included primary diagnostic inpatient codes of 
GBS while the second—more specific—algorithm additionally included OPS codes as 
recommended in the German guidelines for GBS diagnosis and treatment113.  
Preference of the respective algorithm is context dependent. However, regarding the public 
health relevance, a more specific outcome definition is likely closer to the “true” incidence in 
the population and is therefore a more appropriate measure.   
 
Exposure misclassification/misclassification of vaccination status 
The identification of the vaccination status influences the estimation of vaccine impact, 
vaccine effectiveness and vaccine safety issues or the risks of subsequent infectious 
disease-related complications. An inadequate definition of the vaccination status can lead to 
misclassification. 
Administrative claims data have been reported to be the gold standard for assessing drug 
exposure as there is no occurrence of recall bias, i.e., if cases remembered their exposures 
better than controls227. Furthermore, due to the almost complete lack of selection effects 
among participants because of a routine care situation reflected in the data, complete 
information on prescriptions (if they were filled in the pharmacy to get reimbursed by SHIs) or 
procedure codes is available227. Also information on prescriptions of subpopulations that are 
difficult to recruit for field studies, e.g., children, older persons or pregnant women, is 
available in administrative claims data227. Vaccinations can also be identified in 
administrative claims data by outpatient codes used for reimbursement of the administration 
of vaccines (ASHIP-specific EBM codes). However, vaccines are usually not prescribed to 
individual patients but included in the so called “Sprechstundenbedarf” (medical products for 
use at a physician’s office only) which cannot be identified in the database.   
Misclassification of vaccination status can also occur in administrative claims data as no 
information on the antibody level is available (this is also true for all other data sources not 
3 METHODOLOGICAL ISSUES 
 
48 
 
containing laboratory data on antibody level). If vaccinated patients do not show a serological 
antibody response, these patients could be misclassified as vaccinated with an adequate 
immune response but have in reality no immune response and are therefore still prone to 
infection.  
Furthermore, for vaccine safety studies, the definition of the temporal relation between 
vaccination and systemic immunization reactions is challenging as this varies between 
vaccines (e.g., a few hours after the pertussis vaccine; up to several days for the measles 
vaccine), brands (due to different antigens and adjuvants) or individuals (individual immune 
response/reaction).  
Vaccination status misclassification can also occur for vaccinations that have not been 
recommended by STIKO or for vaccinations upon “self-pay” prescription as reimbursement of 
them is SHI-dependent (e.g., for travel vaccinations) and information on these vaccinations is 
thus not completely available in the database which hampers the feasibility of vaccine 
studies for these vaccinations.  
Within the HPV-uptake-study71, only vaccination uptake and not a true coverage could be 
calculated due to the restricted study period of the year 2008 only, for which data were 
available. For coverage estimations, knowledge about the vaccination status before this 
study period would have been necessary, which was not possible due to the lack of specific 
EBM codes. Additionally, the study data refer to a time period shortly after introduction of the 
vaccine in 2007 and thus cannot directly depict the situation in more recent years. However, 
since 2008, HPV coverage remained almost stable over time and the estimated HPV vaccine 
uptake in our study has recently been confirmed in a coverage study based on ASHIP 
data228. Furthermore, a comparison of the HPV uptake data with the official sales figures can 
facilitate quantification of misclassification effects. Despite the limitation to estimate HPV 
coverage data within our study, the estimation of the HPV vaccination coverage per age 
cohort for more recent years would be possible with the GePaRD database by using the 
introduced uniform and specific EBM codes for HPV vaccination across Germany. 
To determine the time interval between an infection of interest (exposure) and the risk of a 
following complication (outcome), it is necessary to know the exact date of both, exposure 
and outcome. While inpatient diagnoses are related to an exact date, outpatient data are not. 
Instead, they can only be allocated to a quarter of a calendar year as outpatient physician 
visits are reimbursed on a quarterly basis. If the exact date of a diagnosis in outpatient data 
is missing, one may use—according to the respective research question—the prescription 
date of a disease-specific drug treatment, EBM or OPS code or an inpatient diagnosis to 
reliably determine an exact date.  
In the SCCS-study33, the main inpatient discharge diagnosis was used to identify an HZ 
infection and the exact date of disease onset was defined by the admission date. For 
3 METHODOLOGICAL ISSUES 
 
49 
 
outpatient data, diagnoses of HZ qualified as ‘certain’ or ‘suspected’ by the respective 
physician were considered and the date of disease onset was defined as the date of 
systemic antiviral prescription (acyclovir, brivudin, famciclovir, valaciclovir). Patients with a 
first outpatient HZ diagnosis and no accompanying prescription had to be excluded as no 
exact date of the exposure could be assessed. Using an approximate date would have 
hampered the definition of exact risk and control periods in the study design (chapter 3.1.6). 
3.2.3 Confounding  
Confounding occurs by “the distortion of the estimated effect of an exposure on an outcome 
due to the association of the exposure with other factors that influence the occurrence of the 
outcome”208. A factor can be defined as a confounder by fulfilling three assumptions: (i) the 
confounder must be associated with the exposure and outcome under study in the source 
population, (ii) the confounder must be a causal risk factor for the disease in the unexposed 
cohort and (iii) a confounder must not lie in the causal pathway (intermediate cause) between 
exposure and the disease208. For example, the socioeconomic status is a potential 
confounder in, e.g., estimating the effectiveness of 13-valent pneumococcal conjugate 
vaccine (PCV13) on pneumococcal disease in children since the socioeconomic status is 
associated with poor health outcomes and vaccination status229. 
In observational studies, it is important to adequately consider confounding factors if the 
information on an individual level is available161. As administrative data are not primarily 
collected for research purposes, important potential confounders regarding the respective 
research questions may be either missing or incomplete, e.g., body mass index (BMI), 
history of smoking, alcohol consumption, lifestyle factors, physical activity, socioeconomic 
status (chapter 1.4.2). If these factors are confounders, unmeasured and/or residual 
confounding could distort the association between exposure and outcome. Consequently, 
this would lead to misinterpretation of the study results. It is therefore highly important to 
check in advance if the potential research questions can be accurately investigated based on 
the available information in the database to achieve valid results.  
 
Time-invariant confounding 
For time-invariant measured confounding, it is possible to restrict the study population to 
individuals who are similar in relation to the confounder or to match the selected controls to 
cases by confounders. This way, a similar distribution of confounders among cases and 
controls could be achieved. Beyond matching by length of follow-up in nested case-controls 
studies in GePaRD, cases and controls are often matched by age at the index date and by 
sex but also by SHI. In the case of vaccine effectiveness or safety studies, matching by SHI 
would be important as differences regarding the “vaccination behavior” (“Impfverhalten”) 
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might exist between different SHIs. Vaccine refusal is associated with factors related to a 
higher socioeconomic status230 and the socioeconomic status differs between the patient 
populations insured by the respective SHIs in GePaRD.  
During the analyses, it is possible to control for confounding by standardization, stratification, 
restriction or adjustment in multivariable analyses. Furthermore, the current “gold standard” 
in observational research is to control confounding by using propensity score (PS) methods 
which can be defined as the probability of a patient receiving the treatment under 
investigation. The PS is used for different procedures: (i) matching on the PS, (ii) building the 
inverse probability of treatment weighting (IPTW), (iii) stratification on PS strata or (iv) 
regression adjustment for the PS231. For unmeasured confounding, other techniques like 
high-dimensional propensity score (HDPS) analyses or instrumental variables may be 
applied to reduce potential confounding during analysis. However, this will not be further 
discussed as this topic is outside the realm of this thesis.  
For unmeasured time-invariant confounders, case-only designs (e.g., case-crossover design 
or self-controlled case-series (SCCS) design) are valuable methods to investigate vaccine-
related research questions and thus a case-only design was applied in the SCCS-study33 
(chapter 3.1.6). The SCCS design implicitly controls for time-invariant confounders as every 
case represents its own control. This is very helpful if not all confounding factors are 
available in the administrative database. 
Time-variant confounding 
The more complicated form of confounding refers to variables that may vary over time. 
However, effects of potentially time-variant confounders (e.g., age or seasonality) can also 
be investigated using the SCCS design by dividing the observation periods according to, 
e.g., age groups or any other relevant time-variant factors.  
Within the SCCS-study33, the follow-up time was stratified by potential cardiovascular risk 
factors that varied over time (e.g., myocardial infarction, transient cerebral ischemic attack, 
atrial fibrillation and flutter identified from inpatient and outpatient diagnoses; use of 
antithrombotics, use of statins identified from outpatient dispensations or age). Furthermore, 
it is possible to analyze stratified estimates according to these risk factors. To investigate 
whether the confounding factors were time-dependent, changes in the prevalence during 
baseline and follow-up were investigated.  
Other examples of time-variant confounders that may bias estimates in vaccine impact 
studies are seasonality, levels of infectious diseases that are prone to outbreaks, weather, 
etc.197 (chapter 3.2.3).  
While a segmented regression analysis is relatively unaffected by time-invariant 
confounders, time-variant confounders can mask or exaggerate the vaccine impact197. 
Examples of time-variant confounders are other events that occur around the same time as 
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the intervention. This could either be (i) other simultaneous interventions targeting the same 
outcome, (ii) seasonal changes in the outcome during the intervention or (iii) changes in 
diagnostic coding patterns or reporting patterns197. It is challenging to disentangle changes in 
incidence rates due to vaccine introduction from changes caused by unrelated factors such 
as secular trends or changes in healthcare utilization, reporting patterns, access to care or 
diagnostic coding practices and the underlying health of the population232.  
If time-variant confounders are known, they can be included in the regression model. 
However, to separate intervention effects from unmeasured or unknown time-variant 
confounding effects the use of control groups may be necessary. This can be done either by 
choosing a group of subjects that is similar to the study group but does not experience the 
intervention and is followed over the same time period as the group with the intervention196 or 
by using baseline data from the outcome during a period when the vaccine had not yet been 
introduced. In this instance, the comparison of the effect between intervention and control 
groups makes it possible to disentangle the real intervention effect from confounding effects 
that could have occurred during the same time as the intervention. In the HPV-impact-
study81, no decrease in age groups other than in the vaccine-recommended female age 
groups was seen which could support the assumption of causality for the decreasing 
incidence in the younger age groups following vaccine introduction. This would also 
invalidate the assumption that other events could have led to a change in AGW incidence as 
AGWs are a specific outcome for HPV-types 6 and 11 infection, that are responsible for 90% 
of AGWs233. This also indicates that specificity of the outcome is highly important in 
investigating vaccine impact in time-trend studies99.  
It is also possible to investigate the same group of subjects while comparing changes of the 
target disease against incidence rates of other diseases during the same time period78,234. 
For example, the effect of PCV13 use on pneumococcus-related hospital admissions has 
been assessed while urinary tract infections and hospital admissions for any reason were 
used as control outcomes234. However, selecting a comparison disease is challenging as 
both the target and comparison disease should share similar biases and causal factors while 
the comparison disease should not be influenced by the intervention99,235. Retrospectively, 
the simultaneous estimation of incidences of STIs other than AGWs would have been 
interesting in the HPV-impact-study81 and could have supported our results.  
A further approach to control for possible time-variant, concurrent events is the multiple 
baseline design. Here, the intervention (e.g., vaccination) is introduced in different 
geographical areas at different times. For example, multiple population subgroups receive 
the intervention time-delayed (e.g., several weeks or months) to observe potential outcome 
changes in relation to intervention introduction at a different time point236. Another approach 
is to add an additional phase, e.g., if the intervention is introduced, withdrawn and introduced 
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again afterwards, in order to investigate a reversal of the effect by the withdrawal197,236. 
Additionally, more complex statistical analyses like splines can be used to control for time-
variant confounders but this will not be further discussed197.   
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4 CONCLUSION AND FUTURE PERSPECTIVES 
This thesis has shown that administrative healthcare data are an important data source for 
epidemiological research of vaccines and vaccine-preventable diseases. Studies conducted 
with this data source require detailed knowledge of the structure of the database and the 
depth of the available information. Furthermore, as it is highly important to avoid bias and 
confounding, careful study planning under the consideration of methodological challenges is 
necessary, some of which have been highlighted and discussed in this thesis. This thesis 
further has demonstrated that not all studies of vaccines or vaccine-preventable diseases 
can be conducted using administrative databases. It is therefore important to precisely 
evaluate the feasibility of a study in advance, e.g., the estimation of the influenza vaccine 
effectiveness is not possible with GePaRD. To continue and improve future observational 
epidemiological studies of vaccines and vaccine-preventable diseases based on 
administrative data sources for the investigation and evaluation of vaccine-related effects in a 
real-world setting, it is necessary to be aware of methodological and data source-dependent 
challenges.  
In the 21st century, vaccine-preventable diseases are relevant national and international 
public health concerns and different challenges regarding vaccines and vaccine-preventable 
diseases may arise in the future. New challenges in the battle against infectious diseases are 
emerging in the course of globalization and related social, demographic and environmental 
changes. The increased mobility and density of the population also increases the rapid 
spread of infectious diseases which has been demonstrated during the hazardous Ebola 
outbreak 2014–2015 or during the severe acute respiratory syndrome (SARS) outbreak 
2002–2003. The potential of the viruses to infect a large number of persons across different 
countries is of great concern and requires coordinated surveillance strategies between 
different countries237. Additionally, ongoing epidemics of tuberculosis, human 
immunodeficiency virus (HIV), malaria and influenza as well as new zoonotic pathogens 
constitute major clinical management challenges worldwide238. Furthermore, the increased 
occurrence of drug- or vaccine-resistant strains (e.g., methicillin-resistant Staphylococcus 
aureus (MRSA), drug-resistant tuberculosis bacteria or drug-resistant malaria parasites)40 will 
create difficulties for the treatment of infections with resistant organisms. These examples 
indicate the importance of developing new vaccines and vaccination strategies (e.g., the new 
vaccine rVSV-ZEBOV against Ebola), the need to expand the use of existing vaccines and 
the tremendous significance of continuously evaluating faster and repeated efficacy and 
effectiveness studies in the future to combat, e.g., pathogen-resistant strains. Additionally, 
new endpoint definitions (e.g., diseases) and different confounding factors might be required 
in future vaccine studies. 
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Fortunately, the progress made in laboratory and medical techniques into pathogen-host 
interactions, pathogenesis and inflammatory pathways as well as the understanding of the 
host’s immune response are leading to the identification and the development of new 
therapies238. In addition to the success of traditional vaccines against infectious diseases, 
there are now also some vaccines available that target infectious agents causing cancer, like 
the HPV vaccine and hepatitis B vaccine. However, the investigation of vaccination effects 
on the primary outcomes of cervical cancer or liver cancer, respectively, among adults will 
take decades. To date, mathematical predictive models can be very helpful to examine the 
long-term effects of vaccination strategies over several decades.  
However, there is also a newer concept of vaccinations. Instead of targeting infectious 
agents, it comprises therapeutic vaccination against chronic diseases. For example, in the 
United States, the cancer vaccine Sipulencel-T (Provenge®) has been approved by the FDA 
for the treatment of metastatic prostate cancer. Against this background, future vaccine 
studies involving therapeutic vaccines against chronic diseases or cancer will face different 
challenges than studies on traditional vaccines as the spectrum shifts. Meaning, while in the 
case of traditional vaccines, the target disease can be linked to the respective pathogen 
(e.g., 99% of cervical carcinoma cases can be attributed to HPV), there is no such 
association for vaccines against chronic diseases. Only a fraction of chronic diseases can be 
referred to the pathogen as most of them are multifactorial, e.g., modifying lifestyle behavior 
or comorbidities that might interact over very long-term periods/decades and develop over 
time can lead to the disease. Other future challenges of vaccine studies could be safety 
concerns, e.g., cancer following SV40-contaminated poliovaccine239 or false suggestions 
regarding long-term AVRs that might result in immediate reductions of vaccine uptake. 
Consequently, the investigation of effectiveness and safety of vaccines against chronic 
diseases is especially challenging as it will take several decades before the respective 
outcomes will occur and it might be even more complex than is the case for current 
traditional vaccines due to the multi-causal nature of chronic diseases.  
These examples show that an administrative database covering data of several decades with 
information on interacting risk factors over long time periods is urgently needed for the 
execution of vaccine studies either on traditional vaccines against infectious diseases but 
also on vaccines targeting chronic diseases.  
Fortunately, the immense importance of such databases has also been acknowledged by 
German legislation. The legal foundation of such databases has been reformed due to the 
introduction of a new European data privacy law. In order to preserve databases such as the 
GePaRD database, an amendment of § 75 SGB X (use of social security data for research 
purposes) will become effective in May 2018. As a result, it will be possible to investigate 
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future long-term vaccine effectiveness, impact and safety issues in a real-world setting in 
Germany.    
The increasingly large amounts of available data require the use of new methods. For 
example, additional information by linkage of electronic healthcare databases with other data 
sources (e.g., surveillance/outbreak systems, disease registries, Disease Management 
Programs (DMPs), biobanks, global laboratory data, etc.) will be necessary for future vaccine 
studies, especially for vaccines against multifactorial chronic diseases. The resulting linked 
data would offer a valid opportunity to rapidly monitor the acute epidemiological situation. 
Furthermore, they could provide additional information (e.g., laboratory parameters on 
individual serological tests and antibody titers, virus strains, biomarkers, biomaterial, etc.) for 
studies on vaccines against chronic diseases requiring specific and different outcome 
definitions (e.g., disease occurrence, remission, competing risks events, overall and cause-
specific survival) or for the development of multivariate algorithms to combine information on 
multiple interacting risk factors for chronic diseases over long time periods, even decades240 
(e.g., lifestyle behavior, comorbidities, medication intake, biomarkers).   
The electronic health record [Ger.: elektronische Gesundheitsakte] could be a valuable tool 
to provide such additional important data. In the form of a longitudinal electronic record 
system, it is envisioned to integrate the medical history, treatment data, medication, allergies, 
vaccination certificates, laboratory data and other health data of the SHI sector as well as 
cross-sectoral and non-medical information (OTC medication, diets, physical activity, etc.)241. 
In theory, this considerably extensive data depth should be completely available in real time 
which could then be used for future vaccine effectiveness and safety studies, particularly 
regarding chronic diseases. However, creating the necessary infrastructure, the resources 
and the technical support242 combined with specific data protection regulations will be a 
tremendous challenge in the future.  
A two-phase design used in electronic healthcare databases could also be a valuable and 
helpful tool to solve some of the above-mentioned challenges of the investigation of future 
vaccine effects. Here, more detailed information from linkage with other databases (e.g., 
DMPs, disease registries, biobanks) could be included, but only for a subgroup of patients 
(phase 2). This additional information could then be used by including data from the entire 
study population (phase 1) to obtain valid results in future studies of vaccines and vaccine-
preventable diseases.  
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